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ABSTRACT 
 
Regulatory T cells (Tregs) are a special branch of T cells which function primarily to keep 
immune responses at a non harmful level and are principally of two types: naturally occurring 
Tregs (nTreg) which develop in the thymus and induced Tregs (iTregs) which develop from 
naïve T cell pools in the periphery. Tregs are widely depicted by their expression of the 
Foxp3 transcription factor and there is an increasing awareness of the existence and activity of 
non-Foxp3 Tregs which also play a role in modulating immune responses. iTregs have been 
extensively studied in recent years and while much is now known about their biology, there 
however exists a knowledge gap about initial signaling events which underlie the process of 
naïve T cell conversion into iTregs in the periphery. With the aid of transgenic T cells specific 
for the pOVA peptide, this study investigated the processes involved in the conversion of 
naïve T cells into CD4+ CD25+ Foxp3- iTregs following activation of the T cell receptors 
(TCRs) on these T cells by weak antigen presenting cells (APC).  
 
Results of this study showed that after activation by weak APC, iTregs initially shed the 
lymph node homing molecule CD62-L and after 24h begin to be re-express this molecule 
again and by 72h, had returned to values as high as in naïve T cells. This was in contrast to T 
cells triggered by mature dendritic cells (DCs) which shed CD62-L just as iTregs but 
maintained consistently low amounts of CD62-L after the initial shedding phase.  Based on 
pharmacological dissection, a differential role for the PI3K/mTOR signaling pathway was 
implicated in the dynamics of CD62-L regulation between iTreg and effector T cells. After 
TCR triggering by weak APC, iTregs exhibited an attenuated phopsho-status at the 
hydrophobic motif of Akt; Ser473 and this signaling profile was found to be associated with 
upregulated levels of the novel molecule PHLPP1 which has been reported to specifically 
target the hydrophobic motif of Akt. Lack of co-stimulatory molecules was also identified as 
playing a critical role in acquisition of regulatory function in T cells triggered by weak APC 
and augmented CD28 stimulation was able to abrogate regulatory function but interestingly 
had no effect on CD62-L expression, thus emphasizing the importance of suboptimal CD28 
signaling for conferment of regulatory behaviour in iTregs but not in modulating its migratory 
potential as assessed by its CD62-L expression level. This work also highlighted the 
differential requirements of PI3K and mTOR signaling for acquisition of regulatory function 
as pharmacological inhibition of PI3K but not mTOR drove T cells from effector lineage into 
regulatory cell lineage.  
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In the final part of the thesis, we began investigating the role of adhesion molecules of the 
microenvironment stroma in T cell activation. Adaptively transferred transgenic OT 2 cells 
were equally activated by transferred antigen laden wildtype dendritic cells with regards to 
CD25 expression but the percentage of proliferating cells was significantly lower in 
Intercellular adhesion molecule (ICAM) deficient mice which lack ICAM expression on the 
stroma of the lymph node  compared to wildtype thus suggesting that in situations of ICAM 
deficiency, T cell immune response might be delayed or insufficient compared to wild type 
conditions. 
 
In conclusion, this present work apart from giving insight into early signaling events in iTreg 
generation also proposes that there exists a temporal window of sensitivity after TCR 
triggering within which the signaling threshold of the PI3K/Akt axis determines cells fate 
lineage into effector or regulatory T cell fate lineage and provides hint that in vivo, adhesion 
molecules on the stroma of lymph nodes play a role in efficiency of T cell responses.  
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1.0 INTRODUCTION 
 
1.1 The Mammalian Immune System 
The immune system is a pathogen fighting system found in invertebrates (at a basic 
rudimentary level) down through to vertebrates which have evolved a more complex system. 
The main function of this system is to eliminate foreign antigens, promote formation of 
immunological memory and drive  the establishment of tolerance to self-antigen (Luckheeram 
et al. 2012). These functions are very important as mammals live in the environment shared 
with several organisms ranging from single cellular to multicellular organisms and most 
times, there will be contact with these organisms co-habiting the ecosystem which may trigger 
disease conditions. To control these incidences, the immune system has evolved and 
developed over several thousand years to produce a tightly controlled mechanism to clear off 
and keep down adverse cellular incidents due to encounters with other organisms or matter on 
the planet. The immune system is made up of various cell types and mediating agents both 
physical and chemical that interlink with one another and several other non-immune cells in 
complex regulatory circuits to effect clearance and protection against foreign harmful antigens 
as well as ensuring tolerance towards self-antigens. On the basis of antigen specificity and 
response timing, the immune system can be divided into 2 somewhat distinct compartments 
which have evolved to tackle foreign body invasion into the body using distinct mechanism, 
viz: the innate and adaptive immune systems (Kindt et al. 2007; Murphy, 2012). 
 
1.1.1 The Innate Immune System 
The innate immune system is non-specific in action (Kindt et al. 2007). Innate immune cells 
recognize tissue insult and pathogen-associated molecular patterns (PAMP) by agency of 
pattern recognition receptors (PRR). One of the key classes of PRR is the Toll-like receptor 
(TLR) family which are type 1 transmembrane proteins with divergent leucine rich 
extracellular domains as well as a highly conserved Toll-IL-IR (TIR) cytoplasmic domain 
(Tabeta et al. 2004). TLR signaling links with intracellular signaling pathways using adaptor 
molecules and generally drives transcription of NF-kB target genes as well as other signaling 
pathways some of which drive initiation of the adaptive immune response in addition to 
shaping terminal differentiation/cell lineage fate decision (Schnare et al. 2001). If foreign 
organisms/matter/antigens manage to get over physical barriers such as the skin and mucosal 
membranes, then they are confronted by the innate immune system which forms the first line 
of defence. The innate response is mediated by phagocytic cells namely  neutrophils, dendritic 
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cells (DCs) and macrophages  in addition to basophils, eosinophils, mast cells and natural 
killer (NK) cells which act in a non-phagocytic manner. DCs and other phagocytic cells 
primarily reside in tissues and act as sentinels monitoring the microenvironment for signs of 
unwanted immune events. In situations that lead to the perturbation of cellular or tissue 
homeostasis, sentinel cells such as DCs and macrophages are the first responders releasing 
chemical mediators such reactive oxygen species (ROS), matrix proteases, chemokines and 
cytokines in addition to biologically active substances such as histamine that boost the 
accumulation of leucocytes at such inflamed (damaged) regions. Concurrently, macrophages 
and mast cells activate vascular and fibroblast responses that facilitate elimination of invading 
organisms and drive local tissue repair. While this response is in play, DCs scavenge up these 
foreign antigens and migrate to lymphoid organs to present these antigens to cells of the 
adaptive immune compartment thus sub-serving their functions as links between the innate 
and adaptive immune systems (de Visser et al. 2006). NK cells also bridge the innate and 
adaptive immune divide by interacting bi-directionally with DCs: some NK cell subsets 
dispose of immature DCs while others drive DC maturation which can then in a feedback 
manner regulate NK cell activation. They act against bacteria and viruses by secreting 
cytotoxic granules which contain cytotoxic granzymes and perforins which attach onto target 
cells thereby inducing programmed cell death.  Distinctive features of NK cells that make 
them generally regarded as innate immune cells are their possession of invariant receptors and 
the fact that NK cell killing is dependent on germ-line encoded receptors with preference for 
molecules on the cell surface of infected or damaged cells (Degli-Esposti and Smyth 
2005;Hamerman et al. 2005). A unique feature of all innate immune cells is the ability to react 
quickly to tissue injury without previous memory of such insults (de Visser et al. 2006). 
 
1.1.2 The Adaptive Immune System 
The acute spontaneous reactions of the innate immune system to cellular homeostatic 
perturbation sets the stage for the activation of the more specific and direct acting adaptive 
immune system. Induction of this system is dependent on interaction between mature sentinel 
cells acting as antigen presenting cells (APCs) and lymphocytes in an inflamed tissue 
environment. Cells of the adaptive immune system i.e. T cells and B cells act in a very 
specific manner due to their expression of somatically generated, diverse antigen specific 
receptors which are formed based on the random gene rearrangements that allow for a more 
broad antigen specific repertoire  than innate immune cells which as aforementioned possess 
germline-encoded receptors. Given this restricted receptor repertoire, clonal expansion of 
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cells bearing receptors specific for antigens of invading pathogens is vital before an adaptive 
immune response can be effectively mounted. This need for clonal expansion is the reason for 
the relatively slow pace of the adaptive immune response when compared to the rapid 
response associated with the innate immune system (Kindt et al. 2007; de Visser et al. 2006). 
Another distinct feature of the adaptive immune system is the fact that following primary 
response, a subset of cells involved in the response go on to differentiate into long lived 
“memory cells” which can drive a more aggressive response were the tissue insult to occur 
again (Murphy, 2012). As aforementioned, T cells and B cells are the 2 main cell types 
involved in mediating the adaptive immune response. 
 
1.1.2.1    B Cells 
B lineage cells play a key role in humoral adaptive immune response and terminally 
differentiate into plasma cells (PCs). B cells act to terminate pathogen activity by secreting 
pathogen specific targeted antibodies which upon binding to these pathogens by the process 
of opsonisation marks these pathogens for phagocytosis by phagocytic cells of the innate 
immune system (Kurosaki et al. 2010).  
B cells develop from lymphoid progenitors in the microenvironment of the bone marrow and 
early steps in their development are dependent on contact between precursor B cells and the 
stromal structures of the bone marrow in addition to occurring in the absence of antigen. This 
phase of development leads to rearrangement of immunoglobulin genes leading to production 
of immature B cells which bear an antigen receptor in the form of cell surface expressed 
immunoglobulin M (IgM) which is capable of interacting with antigens in the environment. 
The production of immature B cells centres around functional rearrangement of the B cell 
receptor (BCR) and is subject to rigid positive and negative selection steps  that eliminate 
overtly reactive immature B cells and end with the licensing of these immature cells to traffic 
to the peripheral lymphoid tissues where they following maturation status begin to express 
immunoglobulin D (IgD) and IgM (Kato et al. 2013).  
Mature naïve B cells circulate in the periphery through secondary lymphoid organs (SLOs) 
until they are activated following an encounter with their cognate antigen and express high 
levels of the chemokine receptor CXCR5 which enables them to respond to CXCL13 
produced by DCs and stromal cells of secondary lymphoid organs in addition to enabling 
them home to the B cell rich follicles of SLOs from where an adequate antibody response can 
be mounted (Kato, Hulse, Tan, & Schleimer 2013;Reif et al. 2002) (Kato et al. 2013; Reif et 
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al. 2002). In order to mount an optimal antibody response, B cells must be activated by helper 
T (Th) cells which inhabit a distinct T cell rich region of the SLO. To bridge this divide, 
follicular B cells via BCR signaling upregulate CCR7 and following its interaction with the 
chemokine CCL21 produced by the high endothelial venules (HEVs) and fibroblastic reticular 
cells of the T cell zone, traffic to the border of the T and B cell zones of the SLO and can then 
interact with cognate Th cells (Cyster 2010;Gunzer et al. 2004). Following on from 
instruction by cognate Th cells, based on strength of BCR antigen recognition and differential 
expression of chemoattractant receptors, primed B cells differentiate into one of three possible 
lineages as either extrafollicular plasma cells, Germinal Centre (GC) B cells or early memory 
B cells that possess the ability to recirculate in the periphery. Cells with strongly activated 
BCRs mostly become extrafollicular cells with concomitant express of the EBV-induced 
protein 2 (EBI2) and increased expression of CXCR4, while those destined to become GC B 
cells do not express EBI2 or upregulate CxCR5 (Goodnow et al. 2010;Paus et al. 2006). This 
interaction of B and T cells is the final step required in the production of terminally 
differentiated plasma cells which can thereafter begin to secrete Immunoglobulins (Ruprecht 
and Lanzavecchia 2006). 
 
1.1.2.2   T Cells 
T cells constitute the other arm of the adaptive immune system next to B cells and are made 
up of a plethora of cells distinguishable based on cell surface expression of different key 
molecules and functionality. T cell precursors originate from a common lymphoid 
haematopoietic stem cell that upon leaving the bone marrow localize to the thymus for 
maturation. The microenvironment of the thymus based on the combination of stromal cells, 
chemokines and cytokines factors make it conducive for the generation of functional T cells 
from the precursors (thymocytes).  In maturation from thymocytes to T cells, T cell receptor 
(TCR) gene rearrangement and thymic selection are vital steps undertaken to ensure that the T 
cell pool contains a vast repertoire of cells capable of recognizing several different antigens 
and also setting the threshold for TCR reactivity/affinity for antigen. During this process, 
thymocytes migrate thorough the microenvironment of the thymus where they make contact 
with peptide major histocompatibility complex (pMHC) on distinct thymic APCs including 
medullary thymic epithelial cells (mTECs), cortical thymic epithelial cells (cTECs) and DCs 
which serve vital functions in shaping the T cell repertoire for antigen recognition, selection 
process and surface expression of such molecules as CD8 and CD4 (Gill et al. 2003;Klein et 
al. 2009).  
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T cell selection, commonly depicted by the affinity model proposes that thymocytes 
possessing TCRs with too weak or too strong affinity for the pMHC are destroyed leaving 
only those with intermediate binding affinity for the pMHC to thrive going on to differentiate 
into mature CD4+ or CD8+ T cells after undergoing the process of positive selection (Daniels 
et al. 2006). TCRs which are vital and indispensible components in the mediation of T cell 
responses are multicomplexed molecular structures consisting of either αβ or γδ chains which 
are bonded with 4 CD3 subunits (γ,δ,ε and ζ). The TCR α chain consists of  V (variable) and J 
(joining) gene segments while the β chain consists of a V, J and D (diversity) gene segment. 
The vast repertoire of antigen specific TCRs is built based on random gene rearrangement 
between exons of the V-D-J segments of the β chain and the V-J segements of the α chain 
(Starr et al. 2003). In addition to the major populations of CD4+ and CD8+ cells produced via 
this process, some T cell precursors by interacting with pMHCs differentiate into non-
conventional T cells such as the CD1d-reactive NKT cells (Luckheeram et al. 2012). While 
the TCR binds with the major histocompatibility complex (MHC) molecule on the APC 
bearing cognate antigen, the CD3 chain mediates T cell activation dynamics (Rudolph et al. 
2006).  
Following completion of the thymic maturation phase, former thymocytes exit the thymus as 
naïve T cells expressing L-selectin (CD62-L), CCR7 and leucocyte function antigen-l (LFA-
1) into the periphery. These molecules confer on the naïve T cell the ability to roll, adhere and 
extravasate through the HEVs in peripheral and mucosal lymphoid structures where these 
naïve cells scan APCs for cognate antigen recognition. Naïve T cell survive for months in the 
periphery due to the influence of pro-survival signals from interleukin 17 (IL 17) as well as 
the low affinity TCR/ self-antigen interaction of the naive T cells (Kindt et al. 2007). As 
aforementioned, there are 2 main classes of T cells produced following thymic maturation, 
viz: CD8+ T cells and CD4+ T cells.  
 
1.1.2.2.1   CD8+ T Cells 
CD8+ T cells otherwise known as cytotoxic T lymphocytes (CTLs) bear the CD8 molecule, 
which is a glycoprotein of about 32-35 kDa (Littman 1987), and is a disulfide-linked dimer 
consisting of an α and β chain each containing an immunoglobulin-like domain linked to 
membrane by a polypeptide. CD8 binds weakly to an invariant site on the α3 domain of the 
MHC class I molecule. MHC class I molecules are restrictedly expressed by non-classic 
APCs including almost all cells of the mammalian system and present peptides from mostly 
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viruses and injured cells to CTLs which have evolved to recognize  and kill such cells. This is 
very important as viruses can infect almost all nucleated cells with the exception of a few 
cases e.g. erythrocytes which are non-nucleated and are thus not known to be subject to 
infection by viruses (Murphy, 2012). CTLs proliferate under the influence of IL-2 with the 
capacity to expand clonally over several multiple hundred folds during a primary immune 
response. This greatly increased ability to expand on a clonal basis compared to CD4+ is 
likely due to the relatively easy activation of the Ag-MHC class 1 complex and generally 
higher survival rate of CD8+ T cells in the general circulation. Rapid expansion and the 
highly specific and selective killing ability of CTLs make them very efficient antigen specific 
effector cells as they are able to kill several target cells while leaving uninfected bystander 
cells unharmed (Broere et al. 2011). 
CTL killing is a contact dependent process requiring the establishment of contact between the 
CTL and its target cell following antigen recognition leading to release of cytolytic granules 
from CTLs into the immunological synapse formed between both cells. There are 2 main 
pathways via which CTLs act on target cells (Berke 1995;Harty et al. 2000); the Ca
2+ 
dependent perforin/granzyme mediated apoptosis and the Ca
2+ 
independent Fas ligand/ Fas-
mediated apoptosis.  Both of these pathways are initiated following TCR signaling and 
ultimately involve induction of apoptotic mechanisms in the target cell (Shresta et al. 1998). 
In the perforin/granzyme killing pathway, lytic granules containing granzymes, perforin and 
the proteoglycan serglycin are transported into target cells as one complex. Following 
secretion, granzymes which are capable of inducing apoptosis via either caspase dependent or 
independent pathways enter into target cells using pores bored into the cell by perforins or by 
receptor induced endocytosis. When mediated by endocytosis, perforin drives the 
translocation of granyzmes from endocytic vesicles into the cytosol of the target cells with the 
proteoglycan serglycin acting as a chaperone to perforin until the complex reaches the plasma 
membrane of the target cells after travelling across the immunological synapse formed 
between the CTL and target cells. This way, granzymes induce apoptosis in target cells 
without inflammation, leaving behind fragments of cell debris that are taken up by 
macrophages (Broere et al. 2011; Kindt et al. 2007).  The second pathway for CTL killing 
activity is via the Fas ligand dependent pathway. In this pathway, the Fas ligand (FasL) 
expressed on the CTL binds onto the Fas receptor (FasR) on the target cell. The Fas molecule 
belongs to the TNF receptor family known to possess an intracellular death domain which 
when triggered initiates caspase dependent apoptosis and is known to be upregulated on the 
cell surface of CTLs following TCR crosslinking. Thus, the binding of FasL and FasR in CTL 
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and target cell interaction 
consequently leads to triggering of 
caspase 1 activation which 
ultimately leads to DNA cleavage 
and cell death in the target cell in a 
non-inflammatory manner (Broere 
et al. 2011; Kindt et al. 2007). 
 
 
 
1.1.2.2.2   CD4+ T Cells 
CD4 is a 55 kDa glycoprotein expressed on the cell surface of many haematopoietic cells 
(Maddon et al. 1987) and is a member of the immunoglobulin superfamily and has 4 
Immunoglobulin domains expressed on the cell surface, the D1-D4 domains. D1 and D3 
domain have semblance to the Immunoglobulin variable (IgV) domains while the D2 and D4 
domains resemble the immunoglobulin constant (IgC) domains. CD4 T cells are restricted to 
recognition and triggering by MHC class II molecules as the CD4 protein only interacts via its 
D1 domain with the β2 domain of MHC class II molecules which are expressed only on 
antigen presenting cells unlike CD8+ T cells which recognize the MHC I molecule. CD4+ T 
cells otherwise called helper T cells are so called because one of their main functions is to 
send signals to others cells of the immune system including B cells and CD8+ cells.  (Kindt et 
al. 2007; Murphy, 2012). Apart from its function in MHC class recognition, CD4 via its 
cytoplasmic tail acts as a co-receptor during TCR interaction with APC. In this role, the 
cytoplasmic/intracellular tail of CD4 serves to amplify TCR signaling by recruiting the Lck 
tyrosine kinase which is central to activation of naïve CD4 T cells (Brady et al. 1993;Foti et 
al. 2002).  
Naïve CD4 T cells ordinarily lack the ability to mount an immune response as they are non-
cytokine secreting cells and only acquire effector functions when activated and differentiated 
into cytokine producing cells. The step of differentiation places a range of possibilities before 
the naïve T cell as based on environmental milieu, cytokine signaling and transcription factor 
expression along with epigenetic tuning, naïve cells can differentiate into different 
subsets/terminal lineages namely T helper 1 (Th1), T helper 2 (Th2), T helper 9 (Th9), T 
helper 17 (Th17) among several other lineages (Boothby et al. 2001; Luckheeram et al. 2012). 
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Apart from the classic CD4 T cell subsets, there is also increasing awareness of the existence 
of cytotoxic CD4 T cells which act like CD8 cells but express the CD4 marker (Appay 
2004;Fang et al. 2012;Marshall and Swain 2011;Quezada et al. 2010) The concept of T cell 
subsets was first introduced by Mossman and Coffman (Mosmann et al. 1986) who found that 
T cells could be divided into 2 groups; an IFNγ producing group and an IL-4, IL-5 and IL-13 
producing group. The importance of this concept was further put in context by the work of 
Locksley and coworkers who found that mice which mounted a predominantly Th1 response 
could clear off Leishmania major while mice with a predominant Th2 cell response could not 
clear off such infection (Heinzel et al. 1989). The array of so far discovered and researched 
CD4+ T cells is enumerated below: 
 
T helper 1 (Th1) 
Th1 cells drive pro-inflammatory cell mediated immunity and have been demonstrated to 
induce delayed-type hypersensitivity (DTH), drive B cell production of opsonizing antibodies 
of the IgG isotype while also mediating the response of the mammalian system against 
protozoa such as Leishmania and Trypanosoma (Broere et al. 2011). They are generally 
involved in fighting immune events involving viral, bacterial and parasitic infections (Stassen 
et al. 2012). In addition, Th1 cells also work closely with CD8+ T cells in mounting 
antitumour responses and are considered the T cell subset with the most potent antitumour 
activity (Dunn et al. 2006;Nishimura et al. 2000). Th1 cells secrete Interferon γ (IFN γ) and 
IL-12 which are also the key cytokines that mediate the signaling cascade needed to drive 
differentiation of naïve T cells into Th1 cells (Trinchieri et al. 2003). During the process of T 
cell activation by APCs, IL-12 is produced in copious amounts by the APC following 
activation of the pattern recognition receptors on the APC and this IL-12 leads to production 
of IFNγ by NK cells which further helps drive Th1 differentiation (Iwasaki and Medzhitov 
2004;Steinman et al. 2003).  
The master regulator for the induction of Th1 cells is the T-box transcription factor (T-bet) 
(Szabo et al. 2000). Additionally, other transcription factors such as STAT1, Runx 3, Eomes 
and Hlx have been implicated in Th1 cell induction (Luckheeram et al. 2012). The T-bet gene 
apart from promoting the differentiation of naïve T cells into Th1 cells also suppresses the 
development of other cell lineages such as the Th2 and Th17 subsets (Afkarian et al. 
2002;Lazarevic et al. 2011;Lugo-Villarino et al. 2003). T-bet expression is strongly driven by 
the signal transducer and activator of transcription 1 (STAT 1) rather than on IL-12 dependent 
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STAT4 which is in turn driven by IFNγ. T-bet has also been demonstrated to drive IFNγ 
production by the differentiating naïve T cell which by a positive feedback mechanism 
amplifies the production of T-bet thereby further perpetuating the differentiation of naïve T 
cells into the Th1 lineage (Afkarian et al. 2002; Luckheeram et al. 2012).  
 
T helper 2 (Th2) 
Th2 cells mediate the non-inflammatory adaptive immune response. They have been 
extensively demonstrated to be intrinsically vital for B cell production of IgA, IgE and IgG 
immunoglobulins and have also been shown to secrete IL-4, IL-5, IL-6, IL-10 and IL-13 
(Luckheeram et al. 2012). In addition to providing support to humoral immune responses, Th2 
cells marshal host defence against helminthic infections and allergic diseases, and generally 
act against extracellular parasites (Zeng 2013). They also mount antitumour activity via the 
recruitment of tumouricidal macrophages and eosinophils into the tumour microenvironment 
which secrete superoxides to breakdown the tumour (Hung et al. 1998).  
IL-4 and IL-2 are important for differentiation of Th2 cells from the naïve T cell pool. In 
terms of transcriptional control, IL-4 induced STAT6 has been shown to drive GATA3 
(GATA-binding protein) which has been identified as the master regulator for Th2 cells 
(Kaplan et al. 1996;Zeng 2013). The transcription factor GATA3 has been demonstrated to 
induce Th2 differentiation through such mechanisms as increased Th2 cytokine production, 
driving selective proliferation of Th2 cells via Gfi-1 recruitment and also by inhibition of Th1 
differentiation by repressing the expression of T-bet possibly by downregulation of STAT4 
(Usui et al. 2003;Zhu et al. 2006). In addition to GATA3, other transcription factors such as 
                  
Figure 1.2 Differentiation of Th1 cells from naïve T cells. Modified from Wilson et al. 2009. 
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STAT5, STAT3, c-Maf and IRF4 have been shown to play roles in Th2 differentiation 
(Luckheeram et al. 2012). 
                 
Figure 1.3 Differentiation of Th2 cells from naïve T cells. Modified from Wilson et al. 2009. 
 
T helper 9 (Th9) 
The Th9 subset is a newly characterized subset which secretes IL-9 and 10, and is currently 
under intense investigation to further clarify its role in the immune response. They are known 
to be pro-inflammatory with a wide spectrum of activity in autoimmune and allergic 
inflammation (Akdis et al. 2012;Shimbara et al. 2000). Specifically, presence of Th9 cells has 
been demonstrated to be an important causative factor in the development and progression of 
allergic airway disease such as asthma. Transcriptionally, 2 master regulators have been 
identified for the Th9 cell subset; IRF4 and and PU.1 which both bind directly on the IL-9 
promoter (Chang et al. 2010;Goswami and Kaplan 2012;Ramming et al. 2012;Staudt et al. 
2010). TGF-β has also been found capable of skewing the differentiation of Th2 cells towards 
Th9 generation. Additionally, TGF-β acting simultaneously with IL-4 has been demonstrated 
to the induce differentiation of Th9 cells from Th2 cells (Veldhoen et al. 2008). 
 
T helper 17 (Th17) 
Th17 cells are IL-17 and IL-22 secreting effector T cell produced following naive T cell 
triggering under the influence of IL-23 and are reported to be widely associated with 
inflammation induced and associated conditions such as rheumatoid arthritis, psoriasis and 
Crohn’s disease (Broere et al. 2011) as well as systemic lupus erythematosus, multiple 
sclerosis and asthma (Dong 2006;Kolls and Linden 2004). Additionally, Th17 cells have been 
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found to play an important role in the pathogenesis of autoimmune encephalomyelitis 
(Aranami and Yamamura 2008). The presence of IL-17 induces expression of pro-
inflammatory cytokines such as IL-6 and granulocyte colony-stimulating factor (G-CSF), 
matrix metalloproteases (MMP) and chemokines (CXCL8, CXCL2). These factors lead to 
macrophage and neutrophil recruitment to sites of infection. Also, IL-22 secreted by Th17 
cells works in a synergistic manner with IL-17 to induce antimicrobial peptides such as β-
defensins in keratinocytes which help to boost the innate immune response against infections 
(Schwandner et al. 2000).  
The major cytokines involved in Th17 cell differentiation are Il-6, IL-21, IL-23 and TGFβ 
with the retinoic acid receptor acid receptor-related orphan receptor gamma-T (RORγt) as 
master transcription factor (Luckheeram et al. 2012). RORα has also been shown to act 
synergistically with RORγt in Th17 lineage committal and its absence has been demonstrated 
to totally abort the development of Th17 cells (Yang et al. 2008). TGFβ signaling is also vital 
to Th17 induction but only at low concentrations and in the presence of IL-6. However, when 
present in high concentrations, TGFβ drives iTreg production via FoxP3 induction (Chen et 
al. 2003;Zhou et al. 2008a). In Th17 differentiation, STAT 3 activated downstream of IL-6, 
IL-21 and IL-23 is important for the induction of the master transcription factor RORγt and 
STAT3 deficiency has been found to drive enhanced expression of T-bet and Foxp3 which are 
master regulators for the differentiation of other cell lineages (Yang et al. 2007). Additionally, 
other transcription factors such as Runx1, Batf, IRF4 and the Aryl hydrocarbon receptor 
(AhR) are known to drive Th17 induction via mechanisms such as inhibition of STAT1 and 
STAT5 signaling which are known to inhibit Th17 differentiation (Kimura et al. 2008). 
               
Figure 1.4 Differentiation of Th17 cells from naïve T cells. Modified from Wilson et al. 2009. 
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T helper 22 (Th22) 
Th22 cells are characterized by the production of IL-22 and contribute to epidermal 
hyperplasia in patients with cases of inflammatory skin disease. While Th17 cells and NK 
cells also produce IL-22 in addition to their main cytokines, cells identified as “Th22” 
produce very high amounts of IL-22 independent of IL-17 dependent mechanisms (Eyerich et 
al. 2009;Nograles et al. 2009). Although initially described as been an offshoot of Th1 cells 
(Gurney 2004), they are now known to be a distinct lineage subset. IL-22 which is highly 
expressed by Th22 cells exhibits antimicrobial defence of keratinocytes by enhancing the 
expression of Calgranulin A, calgranulin B, psoriasin, β-defensin 2 and β-defensin 3, working 
in synergism with IL-17 (Liang et al. 2006;Wolk et al. 2006). Th22 cells are also important 
for the clearance of enteropathogenic bacteria (Basu et al. 2012). In terms of transcriptional 
control, little is known about how Th22 cells are induced but AhR and T-bet have been 
reported to be vitally involved in Th22 differentiation and function along with signaling along 
the IL-6 cascade (Basu et al. 2012). 
 
Follicular Helper (Tfh) T cells 
Tfh cells otherwise known as follicular B helper T cells are a specialized cell lineage which is 
primarily concerned with helping B cells produce antibodies and by their expression of the 
CXCR5 are able to localize to the B cell regions of SLO (Breitfeld et al. 2000). IL-6 and IL-
21 are the key cytokines needed for Tfh differentiation acting via the STAT3 signaling 
pathway in a TGFβ and RORγt independent manner. Inducible co-stimulator (ICOS) is also 
                       
Figure 1.5 Role of Th17 and Th22 cells in inflammation and immunity. Schematic depicting overview of 
cytokine released from Th17 and Th22 during an immune response (Akdis et al. 2012). 
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important for Tfh induction as it has been demonstrated that in ICOSL deficient mice, Tfh 
cells are significantly reduced (Nurieva et al. 2008;Vogelzang et al. 2008).  Recently, Bcl6 
has been identified as a candidate for master regulator status in Tfh induction as its expression 
has been demonstrated to inhibit the production of other cell lineages (Nurieva et al. 2009). 
 
1.1.2.2.3   Regulatory T cells (Tregs)  
Treg cells as a subset include more than one cell type and are important for maintenance of 
peripheral resistance, down modulation of the amplitude of immune responses and prevention 
of autoimmune diseases (Murphy, 2012). The concept of Treg existence and activity was first 
proposed by R. K. Gershon in 1975 (Jonuleit and Schmitt 2003), and finally proven by the 
seminal work of Shimon Sakaguchi and co-workers in 1995 (Sakaguchi et al. 1995). It is now 
known that Tregs play a major role in immunologically relevant situations such as cancer, 
inflammatory conditions and transplant acceptance or rejection and are distinguishable based 
on cytokine profile and cellular markers and differentiation under the influence of antigen 
stimuli (Roncarolo et al. 2006).  
Tregs are mostly differentiated based on the expression of the  Foxp3 transcription factor 
(Roncarolo and Gregori 2008). Foxp3 is a member of the FOX protein family and is widely 
projected as the master transcription factor in Treg development and function (Marson et al. 
2007;Zhang and Zhao 2007). Lack of the Foxp3 gene product scurfin leads to acutely lethal 
lymphoproliferative disease (Khattri et al. 2003). Tregs are generally designated as Foxp3+ or 
Foxp3-. For the Foxp3+ subset, there are 2 major cell types; the induced Tregs (iTreg) and the 
naturally occurring Tregs (nTreg). The Foxp3 subset encompasses both the iTreg and nTregs. 
iTregs develop from naïve T cells in the periphery after antigen triggering as against nTregs 
which are derived from the thymus as a terminally differentiated lineage with the Foxp3 
transcription factor already expressed  (Chen et al. 2003). For iTregs, TGF-β is the major 
cytokine required for their induction from naïve T cells following triggering through the TCR 
(Chen et al. 2003; Luckheeram et al. 2012). Smad2 and Smad3 activation via TGF-β 
pathways also plays a role in Foxp3 induction during iTreg development (Takimoto et al. 
2010). Also important for iTreg induction is the presence of IL-2. IL-2 acting via STAT5 
signaling enhances Foxp3 expression skewing naïve T cells towards the iTreg lineage. 
Conversely, defective IL-2/STAT5 signaling inhibits iTreg development instead favouring 
Th17 induction (Burchill et al. 2007;Davidson et al. 2007). Absence or mutation of Foxp3 is 
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associated with severe systemic autoimmune diseases in mammals (Passerini et al. 2011). 
Aside the classic Foxp3+ iTregs, there are other iTreg populations which are non-Foxp3+. 
The Foxp3- Treg subset of which the T regulatory type 1(Tr1) is the most studied are IL-10 
producing cells which have been shown to be important in suppressing autoimmune processes 
and inflammation. IL-27 and IL-10 have been described as being key cytokines in Tr1 
induction (Awasthi et al. 2007;Gregori et al. 2010). While the mechanism via which IL-10 
acts to induce Tr1 cells is yet to be elucidated, it is known that IL-27 triggers 4 key 
transcription factors necessary for Tr1 induction; c-Maf, IL-21, AhR and ICOS (Apetoh et al. 
2010;Pot et al. 2009).  
The inhibitory activity of Treg require TCR stimulation and are mostly mediated via a cell 
contact dependent mechanism and secretion of such factors as Il-10 and TGF-β (Broere et al. 
2011) and TNF-α (Kindt et al. 2007) among several other factors. These factors function by 
suppressing differentiation of other T cell subsets in addition to prohibiting MHC and co-
stimulatory molecule upregulation on APCs thereby leading to reduced and inefficient 
activation of T cells (Murphy et al. 2012). Other mechanisms such as IL-2 deprivation leading 
to apoptosis (Pandiyan et al. 2007) and blockade of cyclic adenosine monophosphate activity 
(Bopp et al. 2007) have been implicated as means via which Tregs mediate their activity.  Tr1 
cells exert their effect via IL-10 secretion as evidenced via experiments with IL-10 blocking 
antibodies (Levings et al. 2002).  The effect of IL-10 secretion leads to suppression of Th1 
and Th2 immune responses to pathogens, cancer cells and allo-antigens  while supernatants 
from cultures of activated Tr1 cells decrease the potency of DCs in allogeneic T cell 
activation and proliferation (Jonuleit & Schmitt 2003). 
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Figure 1.6 Numerous mechanisms of action of Tregs. Tregs demonstrate different mechanisms for mediating 
suppressory activity some of which are enumerated above (Broere et al. 2011). 
 
1.1.3   Antigen Presenting Cells (APCs) 
For T cells to differentiate and become functional there needs to be TCR triggering/activation. 
This triggering/activation step is performed by a group of specialized cells generally referred 
to as APCs (Reichardt et al. 2010). APCs are extremely important in marshaling an immune 
response as T cells lacks the ability to respond to free unbound antigens and only respond to 
antigen presented specifically on the MHC molecule (Murphy, 2012; Kindt et al. 2007).  
Of all APCs, DCs are the most potent and efficient at T cell activation. They are relatively 
short-lived bone-marrow derived cells which are located in the skin (Langerhans cells), 
airways (within epithelial cells) and in the lamina propria of the gut as well as SLOs. At these 
locations, DCs are immature as denoted by their low expression levels of co-stimulatory 
markers  and highly phagocytic behaviour (MacDonald et al. 2009).  Immature DCs are 
highly endocytic and after encountering vaccine adjuvants or infectious agents using their 
multitude of pattern recognition receptors they take up microbes or other immunogenic 
matter, begin to upregulate co-stimulatory molecules following which they process and 
present peptides on their MHC. The process of change from immature to mature DCs is 
essential to DC antigen presenting capacity as demonstrated by the fact that freshly isolated 
sentinel Langerhans cells are known to be very poor APCs and only after maturation when 
they begin to express very high levels of MHC II molecules of the magnitude of 10
6 
per cell 
do they become efficient APCs (Schuler and Steinman 1985). Following on from this step, 
matured DC exit the tissue and migrate via afferent lymph nodes to the T cell zones of the 
nearest draining lymph node where they initiate immune responses by activating naïve T cells 
(Pulendran et al. 2001;Reis e Sousa 2006). Macrophages in addition to their well-documented 
ability to phagocytose large particulate bodies are also able to break down these bodies and 
present peptides from these foreign matters on their MHC molecules (Murphy, 2012; Kindt et 
al. 2007). However, macrophages due to their lower expression rates of MHC and co-
stimulatory molecules are less efficient APCs than DCs (Santin et al. 1999). B cells while 
researched more for their antibody producing roles are also known to be capable of presenting 
antigens to T cells. It has been argued that the ability of B cells to take up and present 
antigens as peptide fragments is an important step in mounting an adaptive immune response 
(Mitchison 2004). B cells function as APC firstly by recognition and capture of foreign 
antigen by the BCR, then degrading antigen within the internal compartments of the cell and 
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then transporting peptides out of the cell where they are loaded on the MHC II molecules 
following which these peptides are presented to T cells (Yuseff et al. 2013). B cells encounter 
both soluble and large particulate antigens from such cells as macrophages and DCs as well as 
those in the circulation (Qi et al. 2006;Suzuki et al. 2009). B cells have limitations taking up 
large particulate antigens instead favouring soluble antigens. This limitation, could contribute 
to reasons why B cells are regarded as the least efficient APC of all three APCs addressed so 
far (Unanue 1984), in addition to the fact that B cells express extremely low levels of co-
stimulatory molecules (Lenschow et al. 1996).  
There are 2 factors that make for qualifying a cell as an APC. Firstly, such a cell must be able 
to present antigen on their MHC to the TCR in order to trigger what is considered “signal 1” 
which is antigen specific and secondly, to be considered an APC, such a cell should be able to 
provide “signal 2” which is the co-stimulatory input and non-antigen specific (Jenkins 
1992;Schwartz 1990). While DCs, macrophages and B cells meet these requirements to 
different extents, there are other cells such as keratinocytes and epithelial cells which are 
thought to be able to present antigen but lack co-stimulatory capacity and could under 
conditions of inflammation upregulate the co-stimulatory B7 proteins. These cells are 
regarded as non-professional APCs while the former comprising of the macrophages, B cells 
and DCs are professional APCs (Mellman et al. 1998;Nickoloff and Turka 1994;Sprent 1995). 
 
1.1.4   Dynamics of CD4+ T cell Activation 
In order to mount an immune response, T cells need to be activated from their naïve state. 
Naïve cells expressing the molecules CCR7 and CD62-L journey through the general 
circulation and enter into the SLO (mostly lymph nodes) using these homing molecules under 
the influence of a CCR7 gradient. Naïve T cells expressing CCR7 and CD62-L enter into 
SLO structures by trans-endothelial migration through the high endothelial venules of the 
micro-circulation based on their expression of these molecules which enable them to adhere 
and roll on the endothelium of the HEV. After this rolling step on the endothelium, naive T 
cells are “arrested” by the interaction with integrins present on the endothelium following 
which they extravasate through the endothelial layer and get into the lymph node (Arbones et 
al. 1994;Galkina et al. 2007;Weninger et al. 2001). In the lymph node, T cells scan against 
antigen bearing APCs until they find APC bearing cognate antigen (Goodnow and Cyster 
1997;Reichardt et al. 2010). Interactions between APCs and T cells have been shown to be 
dynamic in nature (Gunzer et al. 2000). This interaction leads to binding of the TCR and CD4 
co-receptor onto the MHC II complex and co-stimulatory B7 proteins on the APC to create an 
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immunological synapse. The immune synapse is a dynamic structure consisting of clusters of 
signaling molecules from both T cell and APC with these cells being bound to each other by 
the adhesion molecules LFA-1 and intercellular adhesion molecule-1 (ICAM-1) respectively 
with an inner signaling hub called the central supramolecular activation complexes (c-SMAC) 
which contains the signaling molecules and the peripheral supramolecular activation 
complexes (p-SMAC) made up of adhesion molecule which protect the integrity of the 
structure and maintains the contact for effective T cell activation (Monks et al. 1998;Philipsen 
et al. 2013).  
During T cell-APC interaction, the αβ chains of the TCR which are non-covalently bound 
with invariant chains of the CD3 molecule play a major role in driving T cell activation as its 
multiple immunoreceptor tyrosine-based activation motifs (ITAMs) provide sites for the 
activity of protein tyrosine kinases (PTK) which serve to perpetuate the intracellular signaling 
events necessary for optimal T cell activation, proliferation and differentiation. TCR signaling 
along with CD3 activation sets off cellular and molecular processes involving recruitment of 
downstream kinases such as Lck and ZAP-70 that ultimately lead to proliferation and 
differentiation of these naïve T cells into effector lineages dependent on APC type, 
environmental cue and amounts of co-stimulatory molecules present (Brownlie and Zamoyska 
2013; Tao et al. 1997). Src family kinase members such as Fyn and Lck phosphorylate 
ITAMs leading to recruitment of ZAP-70 via their Src-Homology (SH2) 2 domains. This 
recruitment leads to phosphorylation and activation of ZAP-70 by Lck. pZAP-70 in turn 
phosphorylates SLP-76 and LAT. SLP-70 has been implicated in actin cytoskeleton 
rearrangement which plays a role in immune synapse development dynamics while pLAT as a 
cell membrane adaptor protein provides binding sites for such proteins as Grb2, Ras and PLC-
γ. PLC-γ then plays a critical role in Ca2+ flux as it cleaves 4,5-biphosphate (PIP2) to produce 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) following activation by 
phosphatidylinositide 3-kinase (PI3K). DAG in turn stimulates Protein Kinase C (PKC) and 
the accumulation of IP3, as the activation stimuli persists, it triggers the first wave of 
intracellular Ca
2+
 release that leads to opening of the Ca
2+
 release-activated Ca
2+
 (CRAC) 
channels. Ultimately, these tightly co-ordinated signaling events lead to activation of 
transcription factors such as NF-AT, ELK-1, Jun in T cells and other genes needed to induce 
T cell activation (Brownlie and Zamoyska 2013;Weiss 2010). 
Co-stimulatory signals augment TCR signals to promote proliferation and differentiation. The 
main co-stimulatory molecule is CD28 on the T cell which has the B7 proteins CD80 (B7-1) 
and CD86 (B7-2) on APC as ligands. There are other less potent co-stimulatory molecules 
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involved in T cell activation dynamics such as ICOS, OX-40 and CD27 which are also 
expressed on APCs (Croft 2009;Greenwald et al. 2005). At the inception of T cell activation, 
cytokines initially secreted from the APCs and also from innate immune cells help to drive 
the process and then as the process progresses, the differentiating T cell begin to produce 
cytokines which then by a positive feedback loop perpetuate the differentiation process 
(Luckheeram et al. 2012). After the process of triggering, activated T cells exit the SLO to the 
exterior where they mount an immune response by secreting cytokines (Reichardt et al. 
2013;Seder and Ahmed 2003). This egress is possible based on the downregulation of the 
homing molecules CD62-L and CCR7 as well as the concomitant upregulation of receptors 
which drive homing of T cells to sites of inflammation such as very late antigen 4 (VLA-4), 
P- and E-selectin ligands, and inflammatory chemokine receptors such as CXCR3 and CCR5 
(Forster et al. 2008;Mora and von Andrian 2006). Of extreme importance in T cell egress is 
the upregulation of the sphingosine-1-phospahate receptor on T cells which leads to T cell 
chemotaxis towards high levels of sphingosine-1-phosphate in deep regions of the lymph 
node from where T cell migrates through the LN medulla across medullary cords and sinuses 
before reaching efferent lymphatic vessels which takes the T cells into the general circulation 
(Reichardt et al. 2010). While most of the activated T cells egress as effectors, a percentage of 
them differentiate into memory T cells that retain “immunological memory” and thus retain 
the capacity to respond with even more efficiency and strength against the antigens they 
recognize in a secondary infection (Seder & Ahmed 2003).  
       
Figure 1.7 Schematic of signaling circuit in T cells. APCs with cognate antigen binds onto the TCR of T cells 
while B7 proteins from APCs bind on the CD4 protein in T cell setting off signaling cascades leading to T cell 
activation and the acquisition of functionality based on cytokine profile (Brownlie and Zamoyska 2013). 
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1.1.5   The Role of the PI3K/mTOR Pathway in T cell Activation and Function 
The PI3K pathway is an ancient conserved signaling pathway in metazoans (Wang et al. 
2008a). In T cells this pathway regulates a wide range of functions such as cell growth, 
proliferation, survival, differentiation and metabolism and can be activated by several means 
including TCR activation, co-stimulatory molecule activation, as well as cytokine and 
chemokine receptor triggering (Okkenhaug et al. 2004;Wang et al. 2008a). Triggering of the 
TCR leads to phosphorylation of phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) which is 
recruited to the cell membrane to produce phosphatidylinositol-3,4,5-triphosphate (PIP3) 
(Han et al. 2012). The secondary messenger PIP3 plays a crucial role in initiation of PI3K 
signaling activity. Although present in very low amounts in naïve T cells, this lipid secondary 
messenger is rapidly upregulated following TCR triggering by MHC bearing cognate antigen. 
As the activated T cell remains in contact with APC, PIP3 increasingly accumulates at the cell 
plasma membrane (Costello et al. 2002;Finlay and Cantrell 2010;Harriague and Bismuth 
2002).  Recruitment of PIP3 in turn leads to recruitment of Phosphoinositide-dependent 
kinase 1 (PDK1) as well as Protein Kinase B (PKB) otherwise called Akt. PDK1 then 
phosphorylates Akt at Thr308 and in order to achieve full Akt activation, the mammalian 
target of Rapamycin complex 2 (mTORC2) phosphorylates Akt on Ser473 (Bhaskar and Hay 
2007;Fayard et al. 2010). mTOR activation leads to protein synthesis and regulation of 
metabolic processes needed for growth and cell differentiation as well as survival (Laplante 
and Sabatini 2009;Laplante and Sabatini 2012). Akt activation leads to exclusion of members 
of the Foxo transcription factors such as Foxo1, Foxo3a, Foxo4 and Foxo6 from the cell 
nucleus (Fabre et al. 2005;Hay 2011). Foxo1 has been implicated as a major transcription 
factor driving the production of KLF-2 which in turn drives the promoter regions of the genes 
of the T cell homing molecules CD62-L and CCR7 (Fabre et al. 2008;Sinclair et al. 2008). 
Thus, in addition to being implicated in regulating T cell metabolism after activation, the 
PI3K pathway also regulates T cell migration. This function is important because for T cells 
to function optimally, they have to be at the right site of the body to deliver their cytokines by 
which they influence the immune response (Finlay and Cantrell 2010).  
 
1.1.6   Function of CD62-L in T cells 
CD62-L (L-selectin or Mel-14 antigen) is a cell adhesion molecule which is made up of a 
large highly glycosylated extracellular  Ca
2+
- dependent lectin domain, a single spanning 
transmembrane domain resembling an epidermal growth factor-like region as well as a small 
cytoplasmic tail which are similar to complement regulatory proteins (Phong et al. 2003). 
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CD62-L is expressed on most leukocytes such as neutrophils, T cells and B cells where it is 
involved in the rolling of leukocytes on inflamed endothelial of the vasculature, preceding the 
firm arrest of T cells by interaction with integrins on the vascular endothelium and subsequent 
transmigration/extravasation of these cells through the endothelium into SLOs (Kindt et al. 
2007; Murphy 2012). Naïve T cells circulate continually in the general circulation via the 
lymphatic system and blood through SLOs such as lymph nodes and the protein L-selectin 
plays a key role in driving the migration of these cells into the lymph nodes where they 
encounter antigen (Finlay and Cantrell 2010).  This trafficking of T cells to the SLO begins 
with the attachment of circulating T cells to the high endothelial venules (HEVs) of lymph 
nodes via agency of the interaction between the lectin like glycoprotein L-selectin, expressed 
on T cells and carbohydrates on the endothelium such as the mucin-like ligands, GLYCAM-1 
and CD34. The density of L-Selectin expression per cell is directly proportional to its ability 
to bind onto the endothelium as in vivo studies have shown that cells (both normal and 
malignant) with high level expression of L-Selectin traffic more efficiently to lymph nodes 
than cells which lack this receptor (Kaldjian and Stoolman 1995). Thus L-selectin plays a role 
in localization of cells in vivo as it serves as a homing molecule.  
Following T cell activation, the extracellular domain of L-Selectin is cut by the enzymatic 
activity of the Tumour Necrosis Factor converting enzyme (TNF-Converting Enzyme or 
TACE, also called disintegrin and metalloprotease (ADAM) 17) (Smalley and Ley 2005) 
using an ERK dependent mechanism (Sinclair et al. 2008). Shedding activity  apart from its 
importance in T cell localization is also used as a measure of assessing T cell activation status 
as naïve T cells are denoted by their high expression of CD62-L (Moreau et al. 2012). There 
are however T cell subsets that constitutively express high CD62-L levels, examples of which 
include memory T cells (Sinclair et al. 2008) as well as regulatory T cells (Grailer et al. 
2009), as high CD62-L enable these cells localize to the lymphoid organs where they 
subserve their functions. 
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Figure 1.8 Role of CD62-L in T cell migration to lymph nodes.  Steps involved in T cell trafficking to the 
lymph node depicting the CD62-L dependent steps of T cell capture, rolling and slow rolling following which 
activation of integrins sets in to mediate firm adhesion and subsequent chemotaxis under the influence of 
chemoattractants to the lymph nodes. Modified from Grailer et al. 2009.  
 
1.1.7   The Role of Epigenetics in T cell Differentiation and Function 
Gene transcription is regulated by the complexing of transcription factors onto the regulatory 
regions of genes. In more intricate details, transcription is regulated based on the availability 
of transcription factors, their localization and higher order interactions with other transcription 
factors, co-activators or repressors (Wilson et al. 2005). Accessibility of regulatory regions of 
target genes which is greatly influenced by post-translational modifications (PTM) acting via 
conformational changes in chromatin represent a second level at which gene transcription is 
controlled. These changes which affect chromatin accessibility to transcription factors are 
referred to as epigenetic changes and include such changes as DNA methylation status and 
histone modifications (Berger 2007;Rowell et al. 2008;Wilson et al. 2009). Epigenetics is the 
study of the mechanisms inducing phenotypic changes in cell behaviour which are 
independent of actual DNA sequence changes but are rather driven by conformational 
changes in DNA structures such as the aforementioned modifications of chromatins which 
affect the timing and extent of specific gene expression in a particular cell. Therefore, by 
regulating the chances of transcription factor binding onto gene regulatory regions thus 
limiting access of RNA polymerase II containing complexes necessary for commencement of 
gene transcription, epigenetic factors are able to ablate, attenuate or drive efficient gene 
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transcription (Ansel et al. 2003;Li 2002;Smale and Fisher 2002). Since DNA sequence is 
unchanged, epigenetic modification and attendant phenotypical results they encode are 
heritable traits. This heritability is possible by agency of the DNA methytransferase 1 enzyme 
which faithfully copies methylation patterns from methylated cytosines from parental DNA 
strands onto daughter DNA strands (Wilson et al. 2005).  
DNA methylation is the most well studied of all epigenetic modifications. In mammals, only 
the cytosine residue on CpG dinucleotides of DNA can be methylated via the activity of 2 
types of DNA methyltranferase (DNA MTase or Dnmt) family enzymes which catalyze the 
process of transferring a methyl group to DNA with S-adenosyl methionine (SAM) acting as 
methyl donor. There are 2 types of Dnmts important for induction of DNA methylation 
patterns; Dnmt1 and Dnmt3 which has 2 isoforms; Dnmt3a and Dnmt3b (Bheemanaik et al. 
2006;Malygin and Hattman 2012). DNA methylation is begun by Dnmt3a and DNMT3b 
which induce de novo methylation on unmodified CpG sites and then Dnmt1 is upregulated 
during the S-phase where it is recruited by proliferating cell nuclear antigen (PCNA) and 
preferentially binds onto hemi-methylated CpG sites on dividing cells where it serves to 
maintain methylation patterns similar to those of parent cells. Dnmt1 thus serve as 
maintenance transferases (Okano et al. 1998;Pradhan and Esteve 2003). In general, DNA 
methylation represses gene activity with the notion that gene silencing correlates with DNA 
methylation at promoter regions of such genes while hypomethylation at same region is 
linked to gene activation and expression (Li et al. 2012; Wilson et al. 2005; Wilson et al. 
2009). Next to DNA methylation, histone modification of which acetylation is a major player 
has been implicated and extensively investigated for its role in gene regulation. Reversible 
acetylation of the amino group of lysine in histone tails by histone acetylases 
(HATSs)/histone deacetylases (HDACs) is one of the characterized histone modifications and 
is linked to transcriptional activation/repression respectively. Hyper-acetylated histones are 
transcriptionally active while hypoacetylated histones are transcriptionally inactive/repressed 
(Moreira et al. 2003).  
 In T cell biology, epigenetics plays a major role in the development of T cells from precursor 
stage up to full maturation status in the thymus (Carbone et al. 1988;Wu et al. 1990). There is 
a vast body of literature implicating epigenetic modifications as major players in the 
differentiation process of naïve T cells after activation (Kanno et al. 2012;Thomas et al. 
2012). Naïve T cells when activated with antigen initially secrete low levels of both IFNγ 
(Th1) and IL-4 (Th2) cytokines thus indicating that naïve T cells are poised at the chromatin 
level to respond to signals that drive differentiation. These changes are common to both Th1 
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and Th2 skewing conditions and are known to be independent of STAT4 and STAT6 
signaling along with the transcription factors needed ultimately for cell fate lineage 
determination (Grogan et al. 2001). However, by mechanisms not fully understood, during 
differentiation these cells decide on one cell fate over the other. During this differentiation 
process, cells with Th1 lineage fate begin to exclusively produce IFNγ while silencing the IL-
4 gene transcription and for cells destined for Th2 cell fate, the IL-4 gene locus is activated 
while the IFNγ producing locus is transcriptionally silenced. These changes are underlined by 
changes on chromatin structure and heritably transmitted over multiple cycles proliferation 
and involves several factors such as co-ordination of DNA, histone modifications and 
marshaling of feedback processes that enhance the expression of some genes while 
suppressing expression of others based on cytokine feedback mechanisms (Avni et al. 
2002;Fields et al. 2002;Murphy and Reiner 2002). Epigenetic modifications have also been 
demonstrated as setting the threshold for Th9 cells differentiation by histone modifications at 
the PU.1 gene locus that favour gene transcription (Ramming et al. 2012). In Tregs, the Foxp3 
locus has been shown to be demethylated as against methylation of the same locus in naïve T 
cells (Floess et al. 2007) while on a global level, there have been demonstrated to be over 100 
differentially methylated regions (DMRs) between Tregs and conventional naïve T cells 
including such genes as Foxp3 and IL-2 (Schmidl et al. 2009). Demethylation of the Foxp3 
locus probably licenses the T cell to express the Foxp3 protein which confers regulatory 
ability.  
Another level of epigenetic control of T cell differentiation involves small RNA (RNAi) 
molecules which typically inhibit gene expression. This inhibitory activity is driven by small 
20-30 nucleotide non-coding RNA and was first discovered in Caenorbabditis elegans. There 
are several types of inhibitory RNA such as the endogenous micro RNA (miRNA or miR) and 
the synthetic/exogenous Short Interference RNA (siRNA) (Lee et al. 1993;Wilson and 
Doudna 2013). Of this group of small inhibitory proteins are the miRNAs which have been 
widely studied and are thought to regulate as much as 50% of all genes, with almost all 
mammal cells engaging miRNA processes for gene regulation (Bartel 2009;Friedman et al. 
2009). In T cells, miRNAs are known to regulate such processes as proliferation, survival as 
well as controlling the differentiation process from naïve to effector lineages or regulating 
cytokine production. It is also known that miRNA deficient T cells still maintain their 
capacity to become effectors. It is therefore thought that miRNAs are more important in T 
cells for enforcing differentiation states by inhibiting transcription factors that drive other 
lineage fates. This line of thought is further supported by the fact that miRNA deficient T 
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cells tend to lose their effector status and acquire the characteristics of other T cell subsets 
(Jeker and Bluestone 2013;Muljo et al. 2005;Zhou et al. 2008b). Some known functions of 
specific miRNAs in T cell include and are not limited to the following: miR-10a restrains 
conversion of iTregs into Tfh cells (Takahashi et al. 2012); miR-29ab represses IFNγ (Ma et 
al. 2011;Steiner et al. 2011); miR146a promotes Treg function as well as inhibiting IFNγ 
production in CD4 T effector cells (Lu et al. 2010).  
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1.1.8   Aim of Study 
Based on type of APCs, cytokines present and environmental factors, naïve T cells can 
differentiate into several types of effectors (Reichardt et al. 2010). Previous studies from our 
group have shown that the activation of antigen specific naïve T cells by antigen laden naive 
B cells (TofB) led to the induction of Tregs which could significantly inhibit heart organ 
transplant rejection and ear swelling in an allogeneic context when compared against T cells 
activated by DCs (TofDC) which had an T effector function and phenotype (Reichardt et al. 
2007). TofB cells were found to be CD25+CD62-L+ in contrast to TofDCs which were 
CD25+CD62-L- and could therefore preferentially home to the lymph nodes.  While DCs are 
the major APCs in vivo, it is pertinent to note that there are strong hints in the literature that B 
cells do come into contact with T cells with different functional outcomes (Garside et al. 
1998;Zheng et al. 2009;Zheng et al. 2010).   
The convenience of this co-culture system therefore offered the opportunity to kinetically 
study early signaling events governing Treg development in a model more physiological than 
obtainable with antibody stimulation. This was important as while a lot is known about 
function/signaling in established Tregs, very little is known about the processes governing 
their generation from naïve T cells. This work utilized APCs extensively for T cell triggering 
as against antibody stimulation as this was more physiologically and it is known that antibody 
stimulation dynamics differ from physiological conditions of stimulation by APCs (Arndt et 
al. 2013;Berg et al. 1998;Wang et al. 2008b). Armed with these facts, we set out to investigate 
the following:  
1. What pathways drive the differential regulation of CD62-L following the activation of 
naïve T cells by weak and strong APCs? 
2.  What role does co-stimulatory input play in T cell differentiation with respect to 
acquisition of regulatory properties? Also, does re-expression of CD62-L link acquisition of 
regulatory function and homing behaviour?  
3.  What role does epigenetics play in the differential homing capacities of the TofB, TofDC 
and TofiDC? 
4.  What role does adhesion molecules on the stroma of the microenvironment play in T cell 
activation?  
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2.0 MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals 
Product                                                                                            Manufacturer 
Acetic acid                                                                                             Roth 
Agarose                                                                                              Invitrogen 
Ammonium persulfate (APS)                                                             Bio-Rad 
Aprotinin                                                                                              Sigma 
Bovine serum albumin (BSA)                                                              Sigma 
Calcium Chloride (CaCl2)                                                                    Sigma 
Commassie blue                                                                                   Roth 
Decitabine                                                                                   Selleck Chemicals 
Dimethyl sulfoxide (DMSO)                                                               Fluka 
1,4-Dithiothreitol (DTT)                                                                  Biocheringer 
ECL Western Blotting Substrate                                           Thermo Scientific Pierce 
Ethylene glycol tetraacetic acid (EGTA)                                             Fluka 
Ethanol                                                                                                 Roth 
Ethylendiaminetetraacetic acid (EDTA)                                              Fluka 
Fetal calf serum (FCS)                                                                        bio west 
Gentamycin                                                                                         Sigma 
GM-CSF                                                                                    in house produced 
Glycerol                                                                                                Roth 
Glycine                                                                                                 Roth 
HEPES                                                                                       BIOCHROM AG 
IGEPAL CA-630                                                                                Sigma 
Interleukin-4 (IL-4)                                                                   in house produced 
Isoflurane                                                                                         DeltaSelect 
Isopropanol                                                                                           Roth 
Leupeptin                                                                                            Sigma 
L-Glutamine                                                                               BIOCHROM AG 
Lipopolysaccharide (LPS)                                                                   Sigma 
Ly294002                                                                                          Promega 
Magnesium chloride (MgCl2)                                                              Merck 
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β-Mercaptoethanol                                                                           Fluka 
Methanol                                                                                           Roth 
Non-Essential Amino Acid (NEAA)                                        BIOCHROM AG 
Ova Peptide (pOVA)                             Peptide Core facility, HZI, Braunschweig                                              
Paraformaldehyde                                                                             Roth 
Poly Acrylamide (PAA)                                                                   Roth 
Penicillin/Streptamycin                                                                   Gibco 
Phenylmethanesulfonyl fluoride (PMSF)                                       Fluka 
Ponceau S                                                                                       Sigma  
Potassium chloride (KCl)                                                                Fluka 
Potassium hydroxide (KOH)                                                            Merck 
Protein ladder for western blot                                                     Fermentas 
Protease Inhibitory Cocktail                                                            Roche 
Rapamycin                                                                                  Calbiochem 
Skim milk powder                                                                            Roth 
Sodium azide (NaN3)                                                                       Fluka 
Sodium chloride (NaCl)                                                                   Roth 
Sodium dodecyl sulfate (SDS)                                                         Roth 
Sodium orthovanadate (Na3VO4)                                                    Sigma 
Sodium pyruvate                                                                     BIOCHROM AG 
N,N,N',N'-Tetra-methyl-ethylenediamine (TEMED)                    Bio-Rad 
Trichostatin-A (TSA)                                                                      Sigma 
Tris                                                                                                   Roth 
Trypan Blue                                                                                    Sigma 
Tween 20                                                                                          Roth 
 
2.1.2      Buffers and Media 
2.1.2.1   Complete Medium    
              500ml RPMI Media 
             500μL β-Mercaptoethanol (50 μM) 
              50mL FCS (10%) 
              5mL HEPES (10 mM) 
              5mL L-Glutamine (2 mM) 
              5mL Sodium-Pyruvate (1 mM) 
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               1 x NEAA 
              5mL Penicillin / Streptomycin (100 U/ml) 
 
2.1.2.2   BMDC Medium 
              500ml RPMI Media 
              500µL β-Mercaptoethanol (50 μM) 
              25mL FCS (5%) 
              500µL Gentamycin (50 μg/ml) 
              5mM L-Glutamine (2 mM) 
              250ng GM-CSF 
              25ng IL-4  
              1 x NEAA 
              * Media for generating Immature DCs was exactly the same as above  
                 except that the IL-4 component was totally omitted. 
 
2.1.2.3    Erythrocyte-Lysis buffer 
               4.15 g NH4Cl (0.15 mM) 
               0.5 g KHCO3 (1 mM) 
               1.85 mg Na-EDTA (0.1 mM) 
               Make up volume to 500ml with distilled H2O and sterile filter.  
 
2.1.2.4   PBS 
               80.0 g NaCl (136.9 mM) 
               2.0 g KCl (2.7 mM) 
              14.3 g Na2HPO4 + 2 H2O (8.1 mM) 
              2.0 g K2HPO4 (1.47 mM) 
              Make up volume to 1000ml with distilled H2O and sterile filter. pH 7.4  
 
2.1.2.5   PBS + 1% FCS 
              1000 ml PBS (1x), pH 7,4 
              10 ml FCS   
 
2.1.2.6   MACS-Puffer 
              986.8 ml PBS 
              10ml FCS 
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              3.2mL 0.5M EDTA (0.58 g) 
 
2.1.2.7   Tris Buffered Saline (TBS) (10x) 
              24.22 g Tris-HCl (500mM) 
              80.0 g NaCl (1.5M) 
              Make up volume to 1000ml with distilled H2O and sterile filter add conc.     
              HCl to make up pH to 7.6 
 
2.1.2.8    TBS-T 
               1x TBS + 0.1% Tween-20 
 
2.1.2.9     10% SDS Solution  
                 100g SDS  
                 Add DD H2O to 1L 
                 
2.1.2.10   Electrophoresis Buffer (10x) 
                30.28g      Tris  (0.25M) 
                144.12g    Glycin (1.92M) 
                100ml       10% SDS (1%SDS) 
                Make up volume to 1L with DD H20 
                To make 1x solution, dilute 1 part buffer with 9 part DD H20 
 
2.1.2.11   Transfer Buffer (10x) 
                144.12g    Glycin (1.92M) 
                30.28g      Tris  (0.25M) 
                Make up volume to 1L with DD H20 
 
                To make 1x working solution, mix 
                100ml 10x buffer 
                200ml MeOH 
                700ml DD H2O 
2.1.2.12   Ponceau S Working Solution 
                Ponceau S (0.5%) 
                Methanol (40%) 
                Acetic acid 
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2.1.2.13  Cytoplamic Lysis Buffer “Buffer A” 
               100µl 1M HEPES (10mM) 
               100µl IM KCl (10mM) 
               2µl 0.5M EDTA (0.1mM) 
               1ml IGEPAL (10% IGEPAL) 
               Add DD H2O to 10ml 
 
2.1.2.14  Nuclear Lysis Buffer “Buffer C” 
               100µl 1M HEPES (10mM) 
               20µl 0.5M EDTA (1mM) 
               896µl 4.6M NaCl (0.4M) 
               1ml Glycerol (10% Glycerol) 
                Add DD H2O to 10ml 
 
* Add the following protease inhibitors to both buffers just before use: 
Phosphatase inhibitor 10 mM NaF 
protease inhibitors 0.5 mM Sodium vanadate 
1 mM Phenylmethylsulfonylfluoride (PMSF) 
Protease Inhibitory Cocktail (1/25
th
 volume to total lysis buffer volume) 
 
2.1.2.15   SDS Gel 
              10 x SDS running buffer  
              250 mM Tris 
              2 M Glycine 
              1% SDS 
              pH 8.3 
 
 
 
For an 8×10×0.1 cm gel, the following volumes were used: 
       
              Running gel (12%) 
              4.08 ml deionized H2O 
              3.04 ml Tris-HCl [1,5 M], pH 8,8 
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              4.8 ml PAA 
              120 μl SDS solution [10% (w/v)] 
              16 μl TEMED 
              16 μl APS (25%) 
              
              Stacking gel 
              1.8 ml deion. H2O 
              320 μl Tris-HCl [0,5 M], pH 6,8 
              330 μl PAA 
              25 μl SDS solution [10% (w/v)] 
              12.5 μl TEMED 
              12.5 μl APS [25%] 
 
 
2.1.3   Antibodies and Cell staining 
Western Blot 
Specificity Source Clone Final 
dilution 
Foxo1 Cell Signalling C29H4 1:1000 
Lamin B Santa Cruz - 1:1000 
Anti-rabbit Horseradish 
peroxidase 
Cell Signalling - 1:3000 
Anti-mouse 
Horseradish peroxidase 
Cell Signalling - 1:3000 
 
 
 
 
T cell co-stimulation 
Specificity Source Isotype Clone Final Conc 
CD28 BD IgG2 37.51 10.0 µg/ml 
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FACS 
Surface Antibodies 
Specificity Source Isotype Clone Final Conc 
CD4 PerCP BD Biosciences IgG2a RM4-5 0.33 µg/ml 
CD4 PE BD Biosciences IgG2b L3T4/GK1.5 0.20 µg/ml 
CD4 FITC BD Biosciences IgG2b L3T4/GK1.5 0.33 µg/ml 
CD4 VB 421 Biolegend IgG2b L3T4/GK1.5 0.33 µg/ml 
CD25 PE BD Biosciences IgG1 PC61 0.20 µg/ml 
CD25 APC BD Biosciences IgG1 PC61 0.33 µg/ml 
CD62-L APC BD Biosciences IgG2a MEL-14 0.33 µg/ml 
CD62-L PE BD Biosciences IgG2a MEL-14 0.33 µg/ml 
CD80 PE abcam IgG1 2D10 0.1µg/ml 
CD86 PE-Cy7 abcam IgG2a GL1 0.20 µg/ml 
MHC II FITC eBioscience IgG2b NIMR-4 0.83 µg/ml 
CD11c APC Caltag IgG N418 0.33 µg/ml 
 
 
Intracellular Antibodies 
Specificity Source Isotype Clone Final Conc 
Total Akt FITC Cell Signalling IgG C67E7 0.25 µg/ml 
pAkt Thr308 FITC Cell Signalling IgG C31E5E 0.25 µg/ml 
pAkt Ser473 FITC Cell Signalling IgG D9E 0.25 µg/ml 
Total S6 FITC Cell Signalling IgG1 54D2 0.25 µg/ml 
pS6 Ser235/6 FITC Cell Signalling IgG D57.2.2E 0.25 µg/ml 
pS6 Ser240/4 FITC Cell Signalling IgG D68F8 0.25 µg/ml 
            * Cognate isotype antibodies were applied for proper gating and data interpretation. 
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Fluorescence microscopy 
Specificity Source Isotype Clone Final 
dilution 
Foxo1 Cell Signalling IgG C29H4 1:100 
DAPI Invitrogen - - 1:500 
Rabbit anti-mouse 
2
o 
antibody 
BD 
Biosciences 
IgG2a 11-26c.2a 1:500 
 
 
2.1.4 Kits 
2D QuantKit                                                                        GE healthcare Life Sciences   
Carboxy Fluoroscein Succinimidyl Ester (CFSE)                                          Invitrogen 
Cytoperm/fix kit                                                                                                  BD 
DAPI                                                                                                                Invitrogen 
DNeasy Blood and Tissue kit                                                                          QIAGEN 
Epitect Bisulfite kit                                                                                          QIAGEN 
LS magnetic separation columns                                                                     Miltenyi 
Mice B cell isolation kit                                                                                   Miltenyi 
Mice T cell isolation kit                                                                                   Miltenyi 
MISCRIPT reverse Transcription Kit                                                             QIAGEN 
MISCRIPT RNEasy Isolation kit                                                                    QIAGEN 
ProLong® Antifade Kit                                                                                   Invitrogen 
QIAquick PCR Purification kit                                                                       QIAGEN 
Reverse Transcription Kit                                                                               QIAGEN 
RNEasy Isolation kit                                                                                       QIAGEN 
SYBR green kit                                                                                                QIAGEN 
2.1.5 Primers 
The following primer kits were purchased as ready made from QIAGEN 
Mice PHLPP1 
Mice Actin 
Mice let-7b 
Mice RNUS6 
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Methylation specific PCR for the Klf-2 locus was designed using methprimer. Primer 
characteristics are as given below:  
 
 
CpG Island 1   (Product size: 298kb) 
Primer Tm (
o
C) GC% Sequence 
Forward 54.99 75.00 GGAGTTTTAGGTGTTATTTTTTTT 
Reverse 56.92 66.67 ACCCACCCAAACCTTATAAAC 
 
 
CpG Island 2   (Product size: 142kb) 
Primer Tm (
o
C) GC% Sequence 
Forward 59.93 70.83 GGGGTGTAGGGTAGTAGGAGGTAT 
Reverse 58.33 52.00 CCAATCCCATAAAAAAAATAAAATC 
 
 
2.1.6 Cell Culture Materials and Laboratory ware 
20°C freezer                                                                                       Liebherr Premium  
4 °C refrigerator                                                                                 Liebherr Premium  
80°C freezer                                                                                      Thermo Fischer Scientific  
Bottle top filters (22µM)                                                                   Millipore  
Cell Culture Microscope                                                                   Leica  
Cell culture plates (6, well, 24 well & 96 well round bottom)         Nunc  
Cell strainers (40µm and 70 µm)                                                      BD Falcon  
Centrifuge (mini) 2ml, 1.5ml                                                            eppendorf 
Centrifuge for plastic tubes (15 und 50 ml)                                      eppendorf 
CO2 Incubator                                                                                   Thermo Fischer Scientific 
Culturewell coverslips (12mm)                                                             neo Lab   
Electrophoresis chamber                                                                       BioRad  
Eppendorf tubes (1.5 ml, 2ml)                                                              eppendorf  
FACS Calibur                                                                                       BD Biosciences  
FACS LSR                                                                                            BD Biosciences  
FACS tubes                                                                                           Corning Costar® 
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Falcon tubes (15, 50 ml)                                                                       Greiner bio-one  
Heating block                                                                                        eppendorf  
Ice machine                                                                                           Scotsman 
Micropipettes                                                                                         Gilson  
Neubauer Counting chamber                                                                Marienfeld  
Objective slide                                                                                     Thermo Fischer Scientific 
T3 Kombi PCR Thermocycler                                                              Biometra  
PCR Tubes                                                                                            Greiner bio-one  
Petri dishes                                                                                            Corning                            
pH Meter                                                                                               Schott  
Photometer                                                                                           SmartSpec Plus 
Pipette tips (20 μl & 1000 μl)                                                              Greiner bio-one 
Pipette tips (200 μl)                                                                              eppendorf 
Precision weighing scale                                                                      Sartorius  
SDS PAGE Apparatus                                                                          Bio-Rad 
Sterile bench                                                                                         Haraeus LaminAir 
Syringes (1 ml, 5 ml, 20 ml)                                                                 Omnifix®  
Syringes (1ml)                                                                                      Omnican 
Vortex                                                                                                  Scientific Industries 
Water bath                                                                                            Julabo 
Western blot Apparatus                                                                       BIO-RAD 
 
2.1.7 Software Used  
The following software was used in this work from aspects ranging from word and document 
processing to data analysis and experiment design.  
I. MS office: word processing and data presentation 
II. Flowjo-Tristar: Analysis of FACS data 
III. Graphpad prism: Data presentation 
IV. Fiji-Image J: Image Analysis 
V. Methprimer: Design of primers for Methylation Specific PCR (MSP) 
VI. BiQ Analyser: Analysis of sequences after Bisulfite treatment 
VII. ZEN pro 2011: Data acqusition on Zeiss Apotome microscope 
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2.2  Methods 
2.2.1  Mice 
Wildtype mice of the C57Bl/6 strain were sourced from Harlan Winkelmann, Charles Rivers 
or Jackson labs while Balb/c mice were obtained from Harlan and Jackson labs. Both 
wildtype strains were used as sources of B cells and dendritic cells (mature or immature). OT-
II (based on a C57BL/6 genetic background with recognition for the MHC-II-IAb-molecule) 
(Barnden et al. 1998) and DO.11.10 (based on the genetic background of the Balb/C with 
recognition for the MHC-II IAd molecule) (Murphy et al. 1990) transgenic mice expressing 
TCR complexes engineered to recognize a peptide of chicken-ovalbumin (pOVA AA323-
339) were used as sources of T cells. ICAM-1
_/_ 
knockout mice were obtained from Dr Nancy 
Hogg of the Leukocyte Adhesion Laboratory, Cancer Research UK London Research 
Institute, London, UK. Mice between the ages of 8-16 weeks were sacrificed while under 
deep anesthetic conditions by cervical dislocation following which lymph nodes, bone 
marrow or spleen cells were isolated. 
 
All mice were housed and bred either in the animal facility of the medical faculty of the Otto-
von Guericke University, Germany or the animal facility of the centre for Medical 
Biotechnology (ZMB) of the University of Duisburg Essen, Germany under SPF conditions 
and allowed free access to chow and water ad libitum.   
 
2.2.2 Lymphocyte Isolation and purification 
Mice were killed by cervical dislocation after been put into deep narcosis by use of Isoflurane 
and spleen was removed under antiseptic conditions. The spleen was meshed in a 70μM cell 
strainer/sieve using the piston of a syringe in a petri-dish containing PBS/1 % FCS. Following 
this homogenization process, the cell suspension was centrifuged for 5 min at 400 x g and 
supernatant was discarded. To rid off erythrocytes in the recovered pellet, erythrolysis was 
performed by addition of erythrolysis buffer to the cell pellet (3ml per spleen). The cell pellet 
was resuspended in this buffer for 1 min and left to stand for 4 min at room temperature. 
Lysis activity was stopped by filling up the 50ml tube within which the reaction is occurring 
with PBS/1 % FCS. This suspension was passed through a 70μM sieve to rid off debris and 
the eluent was centrifuged as described above. After centrifugation, the cell pellet was washed 
once with PBS/1% FCS and then after discarding supernatant, cell count was determined. For 
determination of cell count, a 10μl cell suspension aliquot was mixed 1:1 with 0.4% trypan 
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blue, pipetted into a Neubauer chamber for counting under a light microscope. All cells 
stained blue in the Neubauer chamber were excluded as dead cells. 
 
After counting spleenocytes, cells were ready for isolation of either B cells or T cells using 
the Miltenyi negative immune-depletion technique. For every 1 × 10
8
 of total spleenocytes, 
cells were incubated with 20μl MACS buffer and 5μl B or T cell antibody cocktail, incubated 
in a fridge for 10 min and then 15μl MACS buffer with 10μl antibiotin microbeads were 
added with further incubation for another 15 min in a fridge making a total incubation time of 
25 min. After this incubation period, total volume was made up to 10mL with MACS buffer 
and centrifuged to pellet cells. At same time, 3ml of MACS buffer was passed through the 
MACS separation column to equilibrate it. After centrifugation, antibody cocktail and biotin 
microbead stained spleenocytes were suspended in 1ml MACS buffer and put into the 
separation column. 1ml MACS buffer was passed through the separation column 3 times and 
3ml of MACS buffer was passed through 2 times making a total volume of 9ml MACS buffer 
flow-through excluding the original 1ml in which the spleenocytes suspension was initially 
re-suspended in. After this, the MACS column holding all unwanted fractions of cells was 
discarded while the eluent was centrifuged to recover the cells of interest in this case, either B 
cells or T cells. After decanting supernatant, cells were washed in PBS/ 1% FCS, centrifuged 
and the cell pellet was suspended in complete media for downstream applications. Cells were 
usually enriched to purities of about 90-95%, a sample of which is shown below by FACS 
staining. 
 
 
Fig 2.1 Purity of MACS isolated cells. A sample showing T cell purity after isolation using the MACS T cell 
isolation kit showing T cell purity of about 93% as observed following surface staining of T cell by CD 
antibody.  
 
Following cell counting as previously described, cells were seeded in cell culture plates for 
downstream procedures. B cells were typically loaded with pOVA at a final concentration of 
1μg/ml and in some cases, additionally with LPS titrated from 20ng/ml to 1μg/ml and 
incubated overnight before use. T cells were typically immediately after isolation put together 
with APCs. 
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2.2.3 Creation of Dendritic cells from mice bone marrow 
Dendritic cells were created using from modified technique from previously published work 
(Inaba et al. 2001;Labeur et al. 1999) as described hereafter: Mice hind legs were recovered 
and bone marrow flushed out using a 21G needle with syringe filled with PBS/ 1%FCS in a 
Falcon tube. The bone marrow was disintegrated by vigorous pipetting and centrifuged at 400 
x g for 5 min to pellet cells. After discarding supernatant, erythrocytes were lysed using 3ml 
erythrolysis buffer per mice and left to stand for 4 min following which lysis reaction was 
stopped by adding 40ml PBS/1% FCS. This suspension was passed through a 70µM cell sieve 
to rid off debris and the eluent was centrifuged to recover cells. After this centrifuging step, 
cell pellet was washed once more with PBS/1% FCS. After this, the recovered cells were 
placed in 10cm petri-dish with 20ml of either BMDC media or immature DC media 
dependent on cell type been generated. After standing for 2 hours in an incubator at 37
o
C with 
5% CO2, non-adherent cells were collected in supernatant and after pelleting by centrifuging, 
plated in 6 well plates at a density of 3 × 10
6
 cells per 5ml in each well. On day 3 after 
isolation, culture media was refreshed by taking off 2.5ml and replacing with fresh culture 
media. On day 7, non-adherent cells were recovered and after pelleting by centrifuging, 
platted in fresh media and stimulated with 20ng/ml LPS overnight to induce expression of co-
stimulatory molecules. Peptide OVA (pOVA) was added to cell cultures at a final 
concentration of 1µg/ml 2-4 hours before DCs or immature dendritic cells (ImmDCs) were 
used to activate naive T cells.   
2.2.4 In vitro T cell activation 
Antigen specific naive T cells from the spleen(s) of DO11.10 or OT-2 mice were co-cultured 
with mature (or immature) peptide OVA loaded LPS stimulated DC or naive splenic B cells 
from wildtype mice of similar genetic background at a ratio of 1:10 or 1:1 respectively. The 
cell culture medium was RPMI-based and supplemented with 10% fetal calf serum. To obtain 
B-cell– and DC-primed T cells for further downstream applications such as immunoblots or 
realtime PCR in which cell purity is essential for the integrity of analysis, co-cultures 
underwent immunomagnetic depletion of non-CD4 cells using the MACS system at 
designated timepoints as indicated in “Results”.  
T cell activation was modulated pharmacologically using Ly294002 at 1µM, 10µM and 100 
µM (but mostly at 10 µM (Sinclair et al. 2008)) and Rapamycin was used applied at 
concentrations of 10nM, 100nM and 1 µM (mostly at 100nM (Procaccini et al. 2010)). 
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Soluble CD28 was used for co-stimulation at a concentration of 10µg/mL. For investigation 
of epigenetic phenomena, Decitabine was added to co-cultures at 24h into the 72h timepoint 
at 5µM as described (Syrbe et al. 2004) while Trichostatin-A was used added to co-cultures at 
56h during a 72h kinetic  i.e. for 16 hours at 100nM (Moreira et al. 2003). 
 
2.2.5 Proliferation and Inhibitory Assays 
For inhibition assays, B cell (TofB), ImmDC (TofImmDC) or DC (TofDC)–primed T cells 
(with or without pharmacological modulators as indicated in “Results”) were created as 
described in 2.2.4.  Differentially activated T cells were recovered by the MACS system. 
These “recovered” T cells (TofB, TofDC and TofiDC) were then tested for their inhibitory 
capacity by addition to freshly isolated CFSE stained naive T cells primed with pOVA loaded 
DCs at a ratio of 1:1 (T primed: T naive). Readouts for proliferation or activation markers 
were taken at 72h.  
 
2.2.6 Fluorescence Activated Cell Sorting (FACS) 
FACS (otherwise called flow cytometry) exploits the principles of light scatter, excitation and 
emission of fluorochrome molecules to generate specific multi-parameter data from particles 
and cells. This cell biology technique is extremely useful to immunologists for the purpose of 
determining antigen/protein expression levels on cell membranes as well as to determining 
expression levels of intracellular antigens/proteins. In flow cytometry, cells are hydro-
dynamically focused in a sheath of fluid before incidenting on an optimally focused light 
source which are in most cases lasers. As cells or particles of interest incident the light source, 
they scatter this light and fluorochromes are excited to a higher energy state. As the molecules 
return to their original lower energy state, energy is released as a photon of light with specific 
spectral properties unique to different fluorochromes. 
Photo multiplier tubes (PMTs) are detectors which collect the photon emissions from each 
cell or particle which is technically referred to as an "event" and converts them to analog 
voltages. The electrical pulses originating from light detected by the PMTs are then processed 
by a series of linear and log amplifiers. Logarithmic amplification is most often used to 
measure fluorescence in cells. This type of amplification expands the scale for weak signals 
and compresses the scale for strong or specific fluorescence signals. After the different signals 
or pulses are amplified they are processed by an Analog to Digital Converter (ADC) and 
recorded as data files. Optical filters are placed before the detectors so that only wavelengths 
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of light corresponding to specific fluorochrome emissions are collected by each detector (e.g. 
FITC emits in the green region therefore a 30 nm band pass filter centered at 525 nm could be 
used to collect light from this fluorochrome). Light scattered at the same wavelength and 
direction as the laser light, primarily from the surface of the cell, correlates with relative cell 
size (Forward Angle Light Scatter (FSC)) while light scattered 90 degrees to the laser (Side 
Scatter (SSC)) usually from internal structures, correlates with granularity. By correlating 
these two parameters, one can discriminate subpopulations of cells in peripheral blood 
samples, spleen cells, lymph nodes among several others. Signals/events emanating from cell 
debris or aggregates can also be detected and excluded from analysis on the basis of forward 
and side scatter. One unique feature of flow cytometry is that it measures fluorescence per cell 
or particle in contrast to spectrophotometry measures percentage absorption and transmission 
of specific wavelengths of light in a bulk volume of sample. Staining cells with multiple 
fluorochromes conjugated to antibodies or fluorochromes directed at other specific targets 
such as DNA, cytokines, or other proteins distinguishes cell subpopulations which can be 
quantified and also allows more thorough characterization of cell development and activity. 
Flow cytometry data is displayed and analyzed using histograms or two-dimensional dot 
plots. 
One-Parameter Histograms: A one parameter histogram is a graph of cell count on the y-axis 
and the measurement parameter on x-axis. All one-parameter histograms have 1,024 channels. 
These channels correspond to the original voltage generated by a specific light event detected 
by the PMT detector. In other words, the ADC assigns a channel number based on the pulse 
height for individual events. Therefore, brighter specific fluorescence events will yield a 
higher pulse height and thus a higher channel number when displayed as a histogram.   
 
 
 
 
 
 
 
Fig 2.2 A one parameter FACS 
histogram. Depicts cell population as 
a histogram on the x-axis with cell 
count on the y-axis. 
 
Two-Parameter Histograms: A graph representing two measurement parameters, on the x- and 
y-axes, and cell count height on a density gradient. This is similar to a topographical map. 
One can select 64 or 256 channels on each axis of two-parameter histograms. Particle counts 
are shown by dot density or contour plots. 
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Fig 2.3 A two parameter FACS dot-plot. 
Depicts cell characteristics with respect to 
expression profile of 2 molecules, e.g., in 
this blot with CD62-L on the y-axis and 
CD25 on the x-axis. 
 
 
For surface staining, cells were washed in cold PBS supplemented with 1% FCS to rid off 
media. After washing, cells were stained in PBS/FCS buffer with antibodies of interest at 
predetermined concentrations and left to stand on ice for 20 minutes after which cells were 
washed to rid of unbound antibodies and resuspended in PBS/FCS for data/event acquisition.  
For performing intracellular staining, surface antigens of interest were first stained as 
indicated above following which cells were fixed with the cytofix component of the BD 
cytoperm/cytofix kit on ice for 30 minutes. After fixation, cells were centrifuged and after 
discarding fixation buffer washed with the cytoperm buffer which by virtue of its saponin 
component opens up pores in the cells making them accessible to intracellular antibodies. 
Intracellular antibodies dissolved in cytoperm buffer was applied to cells and then incubated 
for 1 hour on ice. After incubation in the presence of antibody, cells were washed in PBS/FCS 
and resuspended in PBS/FCS buffer ready for event acquisition and analysis. 
With respect to event analysis, dead cells were gated out using side and forward scatter 
characteristics and then CD4 positive cells or other cells of interest were gated upon based on 
specific surface antigen staining.  
 
2.2.7 Protein Detection via Immunoblot  
Immunoblotting (alternatively called western blotting) is a method designed to detect a 
specific protein in a given sample of tissue lysate. It utilizes gel electrophoresis as a means to 
separate native or denatured proteins by the length of the polypeptide (denaturing conditions) 
or by the 3-D structure of the protein (native/ non-denaturing conditions). The proteins are 
thereafter transferred onto a membrane (typically nitrocellulose or PVDF) where they are 
probed using cognate antibodies to the protein of interest whose expression profile is under 
investigation. The most common type of gel electrophoresis employs polyacrylamide gels and 
buffers containing the protein denaturing agent, SDS. SDS is an anionic detergent applied to 
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protein sample to linearize proteins and to impart a negative charge to linearized proteins. 
Therefore proteins can be separated according to their electrophoretic mobility (a function of 
the length of a polypeptide chain and its charge). Besides the addition of SDS, proteins may 
optionally be briefly heated to near boiling in the presence of a reducing agent, which further 
denatures the proteins thus overcoming some forms of tertiary protein folding, and breaking 
up quaternary protein structure (oligomeric subunits). SDS-PAGE (SDS polyacrylamide gel 
electrophoresis) maintains polypeptides in a denatured state once they have been treated with 
strong reducing agents to remove secondary and tertiary structure (e.g. S-S disulfide bonds to 
SH and SH) and thus allows separation of proteins by their molecular weight. Sampled 
proteins become covered in the negatively charged SDS and move to the positively charged 
electrode through the acrylamide mesh of the gel. Smaller proteins migrate faster through this 
mesh and the proteins are thus separated according to size (usually measured in kilo Daltons, 
kD). The concentration of acrylamide determines the resolution of the gel i.e. the greater the 
acrylamide concentration of the gel, the better the resolution of smaller molecular weight 
proteins.  
 
 
2.2.7.1 Protein extraction 
Total cell extraction in NP-40 lysis buffer 
After washing cells in ice-cold PBS, following T cell recovery from co-cultures by immune-
magnetic depletion, cells were collected by centrifugation. 5 × 10
6
 T cells were resuspended 
in 80-120μl of Buffer A (with freshly added phosphatase and protease inhibitors) in a 1.5ml 
eppendorf and incubated on ice for 10 min. Cell lysate was then centrifuged at 13,200 rpm for 
10 min 4°C following which the cytoplasmic lysate was carefully transferred into a fresh 
eppendorf tube and immediately stored at -20°C. To recover nuclear proteins, cell pellet from 
cytoplasmic lysis was washed with 100μl of Buffer A (without IGEPAL) and then centrifuged 
after which the buffer was pipetted off. Ice cold Buffer C was added to washed cell pellet and 
incubated with vigorous shaking overnight in a cold room at 4°C. Following this incubation 
period, cell suspension was centrifuged as aforementioned and nuclear proteins carefully 
transferred by pipetting into a fresh eppendorf tube.   
 
 
2.2.7.2 Measurement of protein concentration 
Protein concentrations were determined using the 2D Quantkit (GE healthcare Life Sciences) 
following the manufacturers’ protocol.  
                                                                                                                                                                                      
58 
 
2.2.7.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is used to separate proteins on the basis of their molecular size. The system 
normally involves usage of two gels both contained in one panel: a "stacking gel" with a low 
level of cross linkage and of low pH thus allowing proteins to enter the gel and compact 
without smearing; and a "separation gel" which is of higher pH in addition to having more 
cross linkage, where the proteins are separated according to molecular size.  
Protein samples derived from cell extracts were denatured by heating at 95°C for 5 min in 1 x 
SDS sample buffer, and then cooled immediately on ice. The samples were collected by brief 
centrifugation and then equal amounts of protein were loaded on a SDS gel. The 
electrophoresis was performed with a vertical gel chamber in 1 x SDS running buffer. After 
electrophoresis, the gel containing the separated proteins is used for Western blotting analysis. 
 
3.2.7.4 Western blotting 
The separated proteins were transferred from the gel to a polyvinylidene difluoride (PVDF) 
membrane (Millipore) by wet blotting (Bio-Rad), according to the manufacturer's instructions. 
After blocking in 1 x TBS containing 0.1% Tween 20 and 5% non-fat milk powder or BSA 
for 1-2 hour at room temperature, the membrane was incubated overnight with the appropriate 
primary antibodies at 4°C. 
Following 2-3 washes in TBS-T and 2 washes in TBS each wash lasting for about 6 minutes, 
the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies 
for 1 h at room temperature. After another round of washes as aforementioned, the bound 
proteins were then detected using the Thermo Scientific Pierce enhanced chemiluminescence 
system (ECL). 
 
2.2.8     RNA isolation and gene expression analysis 
qRT-PCR is a molecular biology laboratory technique for amplifying a specific portion of a 
ribonucleic acid molecule. The RNA strand is first reverse transcribed into its DNA 
complement (cDNA), after which this cDNA is amplified using PCR over a predetermined 
number of cycles. This can be accomplished either by a 1 or 2 step process. During the first 
step of RT-PCR called "first strand reaction," cDNA is made from a messenger RNA template 
using dNTPs and an RNA-dependent DNA polymerase (reverse transcriptase) through the 
process of reverse transcription. qRT-PCR takes advantage of a unique feature of mature 
mRNAs; the 3' polyadenylated region, commonly called the poly(A) tail as a binding site for 
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Oligo(dT) DNA primers. These primers will anneal to the 3' end of every mRNA in the 
solution, allowing 5'->3' synthesis of cDNA by the reverse transcriptase enzyme. cDNA can 
also be prepared from mRNA by using gene specific primer or random hexamer primers. 
 
After the reverse transcriptase reaction is complete and cDNA has been generated from the 
original single-stranded mRNA, standard PCR termed the "second strand reaction," is 
initiated. If the initial mRNA templates were derived from the same tissue, subsequent PCR 
reactions can be used to probe the cDNA library that was created by reverse transcription. 
Primers can be designed to amplify target genes being expressed in the source tissue. 
Quantitative real-time PCR can then be used to compare levels of gene expression.  
 
 
2.2.8.1  Isolation of total RNA 
Total RNA was isolated using the Qiagen RNeasy Mini kit following the kit protocol. 
 
 
2.2.8.2  Measurement of RNA concentration 
RNA concentration and quality was determined using the NanoDrop 1000 Spectrophotometer 
(NanoDrop, Wilmington). Isolated RNA purity was checked by ratio of sample absorbance at 
260 and 280 nm (260/280), which should be approximately 2.0 for pure RNA. Sample 
concentration was read in ng/μl based on its absorbance at 260 nm. 
 
2.2.8.3 cDNA Synthesis 
mRNAs were converted by reverse transcription into cDNAs using Oligo (dT) primers and 
reverse transcriptase kit (QIAGEN). Briefly, 200 ng of total RNA from naïve and 
differentially activated T cells and from different timepoints was prepared using the Qiagen 
QuantiTect® Reverse Transcription Kit. For cleaning up the RNA, DNA elimination step was 
undertaken using the following prep.  
 
Genomic DNA elimination Reaction set-up:  
Component Volume/Reaction (µl) 
gDNA Wipeout Buffer, 7x 2 
Template RNA, up to 1 μg* 10 
RNase-free water 2 
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Total reaction volume 14 
 
 
 
Following DNA clean up, RNA was converted to cDNA using the following prep of the 
aforementioned Qiagen kit:  
 
Component Volume/Reaction (µl) 
Reverse-transcription master mix 
Quantiscript Reverse Transcriptase 
1 
Quantiscript RT Buffer, 5x 4 
RT Primer Mix 1 
Template RNA 
Entire genomic DNA elimination 
reaction 
14 
Total reaction volume 20 
# use 2µl 10x miScript Universal Primer when amplifying miRNA and reduce volume of RNase free water to 
keep total reaction volume at 20µl. This step was used in assaying miRNA let7-b levels. 
 
2.2.8.4  Real-time PCR analysis 
Real-time PCR was used to amplify a segment of known/target sequence from cDNA with 
gene specific primers following the protocol of the miScript SYBR® Green PCR Kit. The 
reaction volume is as shown below:  
Component Volume/Reaction (µl) 
2x QuantiTect SYBR Green PCR Master 
mix 
10 
10x Quantitect Primer Assay 2 
Template cDNA 1 
RNase-free water 7 
Total Volume 20 
       # use 2µl 10x miScript Universal Primer when amplifying miRNA and reduce volume of RNase free water 
to keep total reaction volume at 20µl. This step was used in assaying miRNA let7-b levels.  
 
One step Quantitative real-time PCR was performed using either the Qiagen Rotor-Gene Q or 
ABI prism 7000 under the following cycling conditions programme: 
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Steps Temp  Time Cycle no 
Enzyme activation 95°C 15 min 1 cycle 
Denaturation  95°C  15 sec  
40 cycles Annealing  60°C  30 sec 
Extension 72°C  30 sec 
 
The threshold value ct for each individual PCR product was determined manually and ct 
values obtained for the target gene were normalized by subtracting the ct values obtained 
from genes of interest with the reference (housekeeping) gene which was beta-actin for this 
study. Samples were assayed in duplicates and results were derived using the comparative Ct 
method (ΔΔCt). 
 
2.2.9 Methylation specific PCR 
Methylation specific PCR (MSP) is a multistep molecular biology PCR-based method of 
choice for investigating epigenetic modifications induced by gene methylation. Basically the 
technique utilizes Bisulfite treatment of genomic DNA which leads to conversion of 
unmethylated cytosine in the genome to uracil.  
 
                       
Fig 2.4 Chemical depiction of bisulfite treatment of DNA. Source: Tollefsbol T (ed): Handbook of 
Epigenetics: The new Molecular and Medical Genetics. 1
st
 edition. London, San Diego: Academic Press, 2011. 
 
Following this conversion, primers specific for the locus of interest are designed. n. After this 
step of PCR amplification, differences in the DNA of treated samples can be analysed using 
techniques such as sequencing. Overall, results are obtained based on differences in 
nucleotide sequences judging by the presence of uracil nucleotides in the gene sequence. 
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2.2.9.1  Genomic DNA Prep 
DNA preps were prepared from MACS purified T cells following 72 hours of activation by 
either pOVA peptide laden B cells, Immature or mature DCs. Naïve T cells were used as 
control. DNA was extracted using the QIAGEN QIAamp DNA Mini Kit according to the 
manufacturers’ instruction. DNA integrity was checked using the NanoDrop.  
 
2.2.9.2  Bisulfite treatment 
Bisulfite treatment of genomic DNA is an important step in the MSP procedure serving to 
provide a system for differentiating methylated and unmethylated cytosine which is converted 
to uracil following this treatment. For this phase of the work, the QIAGEN Epitect Bisulfite 
kit was used according to the manufacturers’ instruction with thermal cycling conditions as 
shown below:  
 
Step Time Temperature 
Denaturation 5 min 95
o
C 
Incubation 25 min 60
o
C 
Denaturation 5 min 95
o
C 
Incubation 85 min 60
o
C 
Denaturation 5 min 95
o
C 
Incubation 175 min 60
o
C 
Hold Indefinite(overnight) 20
o
C 
 
 
2.2.9.3  PCR 
After Bisulfite treatment and subsequent DNA clean-up using the QIAGEN QIAquick PCR 
purification kit, cleaned DNA was subjected to PCR using the HotStarTaq DNA Polymerase 
from QIAGEN with cognate primers designed to amplify CpG islands previously identified 
on the Klf-2 locus in mouse T cells.  Reaction set-up for the PCR/sample is as shown below:  
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Component Volume/ Reaction 
(µl) 
Final 
concentration 
Reaction mix 
10x PCR buffer 
10 1x 
5x Q-solution 20 1x 
dNTP (10mM of each) 2 200µM 
Forward Primer  1 0.5µM 
Reverse Primer  1 0.5µM 
HotStarTaq DNA 
Polymerase 
0.5 2.5 units/reaction 
Distilled water 61.5 - 
Template DNA 4 1µg 
Total volume 100 - 
 
 
2.2.9.4  Sequencing 
Amplified sequences were outsourced for sequencing at GATC Biotech AG, Konstanz and 
results were analysed using the BiQ Analyzer from the Max Planck Institute for Informatics, 
Saarbrücken.  
 
2.2.10   Immunocytochemistry- Fluorescence Microscopy 
Naïve T cells and differentially activated T cells were recovered working on ice after 
triggering and placed on acid treated 12mm glass slips contained in a 24 well plate. Acid 
treatment increases positive charge on glass slips in order to boost adhesion between slip and 
negatively charges cells. After allowing to stand for one hour to adhere, slips were washed 
with PBS to get rid off complete media. Following on from this, cells were fixed in 4% PFA 
for 30 min and then washed with PBS 3 times. After washing, cells were blocked for 2 hours 
in solution consisting of PBS/ 1% BSA/ 0.5% Tween 20. After blocking, cover slips were 
washed with PBS 2 times and then incubated overnight at 4
o
C in unconjugated Foxo1 
antibody diluted in PBS/ 1% BSA/ 0.5% Tween 20. After overnight incubation, cover slips 
were washed 2 times with PBS/ 1% BSA/ 0.5% Tween 20 and then incubated with secondary 
antibody for 1 hour in the dark at room temperature following which nuclear staining was 
                                                                                                                                                                                      
64 
performed using DAPI. After nuclear staining, cover slips were washed 2 times with PBS/1% 
BSA/ 0.5% Tween 20 and then with PBS alone. For final wash, distilled water was used. For 
mounting, objective slides were coated with 15µl of the Prolong antifade Kit mounting media 
and then cover slips were placed over these  and allowed to stand overnight in the dark at 
room temperature to cure. After this, slides were ready for imaging and data acquisition.  
Mounted cells were imaged using a Zeiss AxioObserver.Z1 and ApoTome at the Imaging 
Centre Essen (IMCES). The Zeiss AxioObserver.Z1 is an inverted epifluorescent microscope 
with a metal halide HXP-120 lamp capable of acquiring DIC and bright field images using a 
Zeiss AxioCam MRm 1.2 Megapixel monochrome charge-coupled device (ccd) camera  with 
a frame size of 1388x1040 pixels. It possesses 4 filters in addition to air, water and oil 
immersion lenses with the Zen 2011 software which affords the opportunity to perform multi-
channel fluorescence image acquisition, z-stacks and time series data acquisition. 
The Zeiss ApoTome uses a structured illumination grid giving wide field optical sectioning 
which slides into the optical path and projects a grid onto the image plane which is laterally 
shifted in 3 predefined steps with an image collected at each step. This set-up serves to rid of 
blurred out of focus fluorescence signals. Thus this system backed up with complex 
algorithms is able to yield enhanced images with better resolution and less blur and out of 
focus planes. For this part of the work, images from T cells were analysed in order to gauge 
the relative amounts of Foxo1 in the nucleus of these cells. Image processing was performed 
using Image J while Foxo1 quantification was done using the cell-pro programme. 
 
2.2.11 Role of adhesion molecules on the stroma of SLOs in T cell activation in vivo 
DC (0.5 x 10
6
) were injected in 20µl PBS into the footpad of age matched wildtype or ICAM-
1
-/-
 mice. As control DC without pOVA were injected into the footpad of a wildtype host. 
After 16 h, 5 x 10
6
 pOVA antigen specific CFSE stained OT-2 cells were injected retro-
orbitally into each host. 72h after the introduction of OT-2 T cells, ipsilateral and contralateral 
popliteal nodes were prepared separately, passed through a 70µM nylon mesh to create a 
single cell suspension and labeled with fluorochrome conjugated antibodies against CD4 and 
CD25. After labeling and washing, events were acquired on a FACS and the CD4 population 
was gated upon and analyzed for proliferation based on CFSE dilution. 
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2.2.12  Statistics 
Data in this body of work are presented as mean +/- SEM from a minimum of 2 independent 
experiments in order to ensure data reproducibility. Statistical significance was determined 
using student’s t-test as provided on the GraphPad software package (Prism Software, 
GraphPad, CA). A p value < 0.05 was considered as statistically significant, p < 0.01 very 
significant and p < 0.001 extremely significant.  
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3.0 RESULTS 
 
3.1 Critical Previous Work 
This thesis builds upon critical previous work which began on the topic. In the previous part 
of the work, it was demonstrated that CD62-L is re-expressed following activation of naïve 
antigen specific T cells by naïve antigen laden B cells (TofB) showing an initial phase of 
CD62-L shedding followed by re-expression at later time points. This was in contrast to the 
dynamics of CD62-L regulation in the same naïve T cells triggered by matured DCs. Using 
the pharmacological agents PD184352 and TAPI-2 which inhibit MEK-Erk phosphorylation 
and TACE shedding respectively, the underlying mechanism for initial shedding was found to 
be Erk mediated TACE sheddase activity. In terms of long term regulation, the PI3K/mTOR 
signaling axis was found to mediate sustained downregulation of CD62-L in TofDC but not in 
TofB where addition of pharmacological agents could induce no upregulation of CD62-L as 
was observed in the case of the TofDC.  
The next phase of the work involved investigating CD62-L regulation on the transcriptional 
level. In summary, the expression levels of 2 key transcription factors; KLF-2 and CD62-L 
which have been reported in the literature to regulate CD62-L transcriptional activity were 
investigated by real time PCR in a kinetic manner. It was observed that following activation 
of antigen specific T cells by either antigen laden DC or B cells, CD62-L and KLF-2 mRNA 
were equally downregulated 24h after activation but while levels remained low in the TofDC, 
both mRNAs were re-expressed as at the 72h timepoint. Targeting the PI3K/mTOR pathways 
with Rapamycin or LY294002 was shown to induce re-expression of both CD62-L in the 
TofDC and had only a short term effect on TofB failing to induce any upregulation of both 
mRNAs at 72h. These results are published together with other data generated in this thesis in 
the paper; Etemire et al. 2013.  
 
3.2 Rapamycin and Ly294002 regulate CD62-L in a dose dependent manner 
To further gain insight into the regulation of CD62-L via the PI3K/mTOR signaling pathway, 
we titrated the concentration of Rapamycin and Ly294002. Having previously used 
Rapamycin at 100nM we titrated this inhibitor at 10nM and 1µM concentrations.  mTOR 
signaling occurs via 2 complexes; TOR Complex 1 (TORC1) and TOR Complex 2 (TORC2). 
TORC1 is Rapamycin sensitive contains Rheb, regulatory associated protein of mTOR 
(raptor), G protein β-subunit-like protein (GβL), protein kinase B/Akt substrate 40 kDa 
(PRAS40). This complex is linked with phosphorylation of such targets as the ribosomal S6 
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kinase (S6K1). TORC2 is considered Rapamycin insensitive and contains the Rapamycin-
insensitive companion of mTOR (rictor), GβL, mammalian stress activated protein kinase 
interacting protein-1 (mSin1) as well as mTOR (Delgoffe et al. 2009).  Concentrations up to 
about 150nM of Rapamycin inhibits TORC1 while usage at doses from 500nM  inhibit 
TORC2 and induce cell death (Foster and Toschi 2009). 
mTOR inhibition by Rapamycin had no influence on CD62-L expression profile of both TofB 
and TofDC at 6h. However, at 24h a divergent pattern of response to the inhibitor began to 
appear. In TofB, CD62-L expression level increased from 48% to 58% when treated with 
10nM Rapamycin and 62% at 100nM while in TofDC, CD62-L levels increased from 24% to 
40% when treated with 10nM Rapamycin and 53% at 100nM (Figure 3.1a).  
         a) 
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At the supra-optimal concentration of 1µM, both cell models began to show signs of cell 
death. At 72h, the upregulating effect of Rapamycin on CD62-L was lost in the TofB as the 
level remains constant in both untreated TofB as well as the 10nM and 100nM Rapamycin 
treated samples. This was in contrast to the TofDC where Rapamycin at 10nM induced no 
upregulation while inducing a rise from 15% CD62-L expression in untreated TofDC to 50% 
         b) 
                             
Fig 3.1 Effect of mTOR and PI3K inhibitor titration on CD62-L expression levels. Antigen specific naïve 
T cells were triggered with pOVA laden naïve B cells (TofB) or DC (TofDC) for specified timepoint in the 
presence or absence of inhibitors. Subsequently, CD62-L dynamics was analysed by gating on T cell 
population from events acquired by flow cytometry. (A) One representative FACS blot depicting dose 
dependent regulation of CD62-L in T cells by the mTOR inhibitor Rapamycin. (B) One representative FACS 
blot showing the dose dependent regulation of CD62-L in T cells by the PI3K inhibitor LY294002. Data are 
representative of 3 independent experiments. 
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in TofDC treated with 100nM. In both cell models, treatment with Rapamycin at 1µM 
induced cell death. 
Titration of the PI3K inhibitor LY294002 was performed at 3 different concentrations; 1µM, 
10µM and 100 µM. A 6h in both TofB and TofDC, PI3K inhibition had no discernible effect 
on CD62-L expression levels at 1µM and 10µM while signs of cell death were already visible 
in cells treated with 100µM LY294002. In the TofB at 24h, CD62-L expression was increased 
from 33% to 43% and 51% in 1µM and 10µM treated samples respectively. This pattern of 
upregulation was also observed in TofDCs which showed increase from 19% to 28% and 45% 
CD62-L expression when treated with LY294002 at 1µM and 10µM. however, supra-
effective levels of LY294002 at 100µM induced cell death. Data at the long-term timepoint of 
72h showed that at this timepoint, in TofB PI3K inhibition had no effect on CD62-L 
expression while the upregulation of CD6-L in TofDC following LY294002 application was 
sustained and even potentiated with values rising from 27% in untreated cells to 66% and 
78% in 1µM and 10µM treated cells respectively (Figure 3.1b).  
These results are in agreement with data from Sinclair et al. 2008 which reported upregulation 
of CD62-L following PI3K and mTOR inhibition . This data also indicate that previous work 
reported under “Previous Work” had been conducted with these inhibitors at an optimal 
physiological concentration and also indicate very strongly that the PI3K/mTOR signaling 
pathway is involved in the regulation of CD62-L in both TofB and TofDC.  
 
3.3 CD62-L dynamics is independent of lipopolysaccharide (LPS) induced Toll Like 
receptors (TLR) activation in B cells 
Having implicated the PI3K/mTOR axis in CD62-L regulation in both cell model systems, we 
moved on to identify new pathways that might perhaps drive this differential regulation of 
CD62-L. TLR triggering has been demonstrated to induce loss of CD62-L in B cells 
(Morrison et al. 2010) and naïve B cells express low amounts of TLRs (Ruprecht & 
Lanzavecchia 2006) as opposed to DCs which due to their innate immune functions 
abundantly express these receptors (Edwards et al. 2003;Schreibelt et al. 2010).  To test our 
hypothesis that the increased presence and activity of TLRs on DC might be responsible for 
the differential regulation of CD62-L on TofDC vs TofB, we decided to trigger TLR on B cell 
using LPS as it has been previously demonstrated by LPS is a potent trigger of TLRs 
especially TLR4 which is highly expressed on DCs (Acosta-Rodriguez et al. 2007;Chow et al. 
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1999;Hoshino et al. 1999). LPS triggering of TLRs has been demonstrated mice and human T 
cells (Zanin-Zhorov et al. 2007) as well as in B cells (Ruprecht & Lanzavecchia 2006). 
LPS was used at both the regular concentration used for maturation of DCs in this thesis 
(20ng/mL) as well at a high concentration of 1ug/mL. At 6h, T cells activated with B cells 
and 20ng/mL LPS added in culture showed similar CD62-L kinetic to TofB while there was a 
marked reduction in CD62-L expression of T cells triggered with 1µg/mL LPS in culture 
solution. The decrease in CD62-L expression was transient as T cells triggered with LPS 
treated B cells showed similar % expression of CD62-L as the regular TofB at 24 and 72h 
(Figure 3.2a). Also, LPS incubated TofB cells were able to induce faster upregulation of 
CD25 than non LPS treated TofB cells. However, at the terminal timepoint of 72h, TofB 
generated in the presence or absence of LPS expressed equal amounts of CD25 (Figure 3.2b). 
This experiment was repeated in a modified manner where B cells were treated overnight with 
LPS at 20ng/mL and 1µg/mL before being used in co-culture with T cells to generate TofB  
(data not shown). Under these conditions, CD62-L and CD25 kinetics were indistinguishable 
from the results reported above. 
On the basis of these observations, we could exclude a role for the innate signaling 
mechanism of TLRs in the dynamics of CD62-L as well as CD25 regulation in the T cells in 
this study. It was also instructive that even with the direct addition of the potent TLR trigger 
LPS in culture, TofBs CD62-L dynamics was unchanged thus further suggesting that CD62-L 
regulation in this context is independent of TLR activity. This data thus strengthened the need 
to focus on signaling events driven directly by TCR stimulation as it did appear that receptors 
and mechanisms from the innate arm of the immune system were not vitally important for 
subserving the functions under investigation and might play no discernible role in iTreg 
induction in the system under investigation here. 
 
             a) 
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                 b) 
       
Fig 3.2 Role of TLRs in the regulation of CD62-L in TofB. TofB and TofDC was prepared as previously 
described with LPS added at indicated concentrations. CD62-L and CD25 dynamics were analysed by gating 
on the T cell population from events acquired by flow cytometry. (A) CD62-L levels in TofB with or without 
LPS in culture. (B) CD25 expression levels in TofB with or without LPS in culture. Data are means + SEM of 
3 independent experiments. 
 
3.4 Readout of mTOR induced S6 phosphorylation status as a surrogate marker for 
PI3K activity in TofB and TofDC 
Based on the observation that the PI3K inhibitor LY294002 as well as the mTOR inhibitor 
Rapamycin both exerted the same influence on the dynamics of CD62-L regulation in the 
TofB vs the TofDC (with Rapamycin showing less potent effect), we hypothesized that 
differences in the underlying signaling pathway of the PI3K/mTOR signaling axis might be 
responsible for this disparity in CD62-L expression. This would offer explanation as to why 
silencing of these pathways which are activated following TCR triggering was able to 
upregulate CD62-L in the TofDC back to naïve T cell expression levels. To test this 
hypothesis, we investigated the phosphorylation status of the mTOR downstream effector 
molecule, S6. Phosphorylation status of the S6 protein has previously been used as a readout 
for PI3K activity by Levings and co-workers (Crellin et al. 2007). We investigated in a kinetic 
manner from 6, 24 and 72h the expression of pS6 looking at 2 different phospho-sites; 
Ser235/236 and Ser240/244  in addition to examining total S6 expression. Total S6 levels 
were more or less constant between TofB and TofDC at all timepoints examined and no 
significant differences were observed (Figure 3.3a). For both phosphorylation sites examined 
in Figure 3.1b-c, there was no significant difference found between TofB and TofDC as well 
across all timepoints investigated. It was however observed that as a trend, pS6 Ser235/6 
expression levels were very even between both cell models as against the decreased albeit not 
in significant d levels in pS6 Ser240/4 status in the TofB at 72h which was lower than that of 
pS6 expression levels in TofDC (Figure 3.3b-c). These results indicated that there was some 
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regulation at the S6 level in both TofB and TofDC but did not fully clarify the signaling 
profile of the PI3K/mTOR axis with respect to CD62-L regulation in both cell models.  
 
a) 
 
b) 
 
c) 
 
  
Fig 3.3 pS6 as surrogate readout for PI3K/mTOR signaling. TofB and TofDC were prepared and acquired as 
events by flow cytometry following which the T cell population was gated upon. (A) Time course of % 
expression for total S6 in T cells (B) Time course of % expression for pS6 Ser235/6 in T cells (C) Time course 
for % expression of pS6 Ser240/4 in T cells. Data are means + SEM of 5 independent experiments. 
 
3.5    Induction of Tregs using immature DC (iDC) as weak APC  
Having performed the study so far with B cell as weak APC, we decided to incorporate a 
more physiological weak APC into the study. The reason for this being that while it is  known 
that B cells interact in vivo with T cells, it is still a matter of discussion as to the functional 
relevance of these interactions (Barr et al. 2007). In filling this gap, DCs were of choice 
because while they function as the most potent APC under conditions of inflammation, in 
non-inflammatory situations when they exist in an immature state and function to induce self-
tolerance by inducing iTregs in vivo (Dudziak et al. 2007;Ohnmacht et al. 2009;Steinman and 
Nussenzweig 2002). Based on these facts, we generated immature DCs for use as additional 
APC for the remaining part of this work.  
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3.5.1 Generation and characterization of immature dendritic cells (iDCs) 
iDC were generated using the same technique as BMDC generation but in the absence of IL-4 
as culture media containing GM-CSF only has been demonstrated to induce an immature 
phenotype in bone marrow derived cells (Lutz et al. 2000). Cells were characterized with 
respect to 3 key markers; CD11c, MHC II and B7 (CD80 and CD86) protein expression 
levels. Only few cells of the iDC population generated expressed MHC II and those which did 
had similar expression levels as matured DCs. CD11c and B7 protein expression were 
markedly lower in iDC compared to DC (Figure 3.4a). On the basis of % expression, iDCs 
expressed about 3 times less MHC II than DCs while DCs expressed 50% more CD11c than 
iDCs. In terms of B7 protein expression, DCs were 95% and 90% positive for CD80 and 
CD86 expression respectively. This was in contrast to iDCs which had expression levels of 
about 80% for both B7 proteins (Figure 3.4b). While these percentages do not reveal very 
prominent differences in the phenotype of DCs vis a vis iDCs, analysis on per cell basis 
revealed in more details important differences between both cell types. While MHC II was 
more or less equally expressed on both cell types, CD11c expression was about 5 times higher 
in DC than iDCs (Figure 3.4c). With regards to co-stimulatory molecule expression, DCs 
expressed about 4-6 times more CD80 and 3-5 times more CD86 than iDCs (Figure 3.4d).  
These results validated our system for the generation of iDCs in addition to hinting very 
strongly that iDCs will function as far less efficient APC than DC and fit very nicely into our 
study as we characterize the dynamics of differential T cell activation based on APC 
efficiency. 
 
a) 
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b) 
 
c) 
 
d)     
 
  
Fig 3.4 Characterization of iDCs against mature DCs. iDC was contrasted against matured DCs to measure 
the relative expression of lineage markers, stimulatory and co-stimulatory molecules. (A) One representative 
FACS blot showing expression of markers investigated. Solid lines depict expression profile of target 
molecules while dotted lines are isotype controls (B) Comparison of % surface expression of MHC II, CD11c 
and B7 proteins on DC and iDC. (C) Per cell analysis show that DC express more CD11c than iDC while both 
cells possess equal amounts of MHC II (D) cell cell analysis reveal that DCs express more co-stimulatory 
molecules than iDC. Data are means + SEM of 2 independent experiments. 
 
3.5.2 Immature DC triggered T cells show the same Phenotypic Characteristics as TofB  
Next to generating TofiDCs, it was important to characterize them in terms of key molecules 
whose expression patterns are presently known in the TofB. TofBs have been reported as 
being CD25
+
CD62-L
+ 
as well as Foxp3
-
 (Reichardt et al. 2007). After analysis of T cells 
activated by iDC (TofiDC), we observed that TofiDC were about 90% positive for CD25 thus 
expressing values similar to the TofB and TofDC (Figure 3.5a). Interestingly, TofiDCs just 
like both other differentially activated T cells in this study were found to be Foxp3
-
 (Figure 
3.5b). Next to characterizing CD25 and Foxp3 expression status, we turned to investigate the 
dynamics of CD62-L expression in TofiDC during the co-incubation phase of their 
generation. Here we found that TofiDC regulated CD62-L expression in a manner similar to 
TofB.  Initially, T cells triggered by iDC shed CD62-L at the early timepoint of 6h but 
starting from 24h onwards began re-expressing CD62-L up to levels which were significantly 
higher than the expression rate in TofDC. However, despite the fact that there was no 
significant difference between TofB and TofiDC at 6h and 24h, CD62-L expression level 
were significantly higher in the TofB and TofiDC at 72h compared to TofDC (Figure 3.5c-d).  
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These results showed that the iDCs generated were still more potent APCs than B cells but for 
the fact that they could induce T cells in a manner similar to B cells acting as APCs, we 
considered the TofiDC a suitable cell type for incorporation into our study subject to 
functional testing which should show that they do possess regulatory function just as TofB. 
       
3.5.3 Functional characterisation of TofiDC and delineation of the involvement of the 
PI3K and mTOR pathways in acquisition of regulatory function 
Having characterized TofiDCs phenotypically, we set out to characterize them functionally in 
order to gain information as to whether or not they exhibit regulatory behaviour while at same 
time looking to see if mTOR and PI3K inhibition-induced CD62-L upregulation in TofDC 
could lead to induction of regulatory function in the inhibitor treated TofDCs. This question 
was asked based on the hypothesis that incomplete signaling via the mTOR/PI3K pathway 
drove upregulation of CD62-L in TofB as well as in TofDC were subjected to incomplete 
signaling profile of these pathways via pharmacological interference using Rapamycin and 
a) 
 
b) 
 
c) 
 
d) 
 
Fig 3.5 Phenotypic characterization of T cells triggered by iDC. Antigen specific naïve T cells were 
triggered with antigen laden iDC to produce TofiDCs in addition to co-cultures for TofB and TofDC.  
Expression profiles of specific markers were assessed by flow cytometry and analysis performed on the T 
cell gated population. (A) CD25 is expressed in TofiDC at the same levels as TofB and TofDC. (B) 
Foxp3 expression was not upregulated in TofiDC, as well as in TofB and TofDC. Naïve T cells were 
assigned a value of 1 for analysis. (C) One representative line graph of CD62-L regulation in TofiDC vis 
a vis TofB and TofDC. (D) Statistical analysis of CD62-L expression in all three cell types show that 
TofiDC CD62-L dynamics mirror that of TofB and is significantly higher than on the TofDC. Data for 
Figures a,b and d represent means + SEM of 3-4 independent experiments. 
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LY294002. In addition to this, we hypothesized that re-expression of CD62-L following 
activation of T cells perhaps links homing behaviour and acquisition of regulatory function. 
To test our hypothesis, in vitro T cell activation assays were performed wherein we examined 
2 parameters in order to judge the activation and proliferation status of naïve T cells under the 
influence of these differentially activated/primed T cells: firstly CD25 expression and 
secondly, CFSE dilution. Our data showed that after 72h of assay, as expected, naïve T cells 
left standing alone did not upregulate CD25. In contrast to this, naïve T cells incubated with 
antigen laden DC were 97% positive for CD25 and this was unchanged even with the addition 
of TofDC and TofDC+Rapamycin modulator samples to the co-culture. However, same T 
cells incubated with DC separately could only induce about 41-47% CD25 expression when 
co-cultures were performed in the presence of the modulators TofB, TofiDC as well as 
TofDC+LY294002. This result was of great interest as it gave strong hints to the fact that 
although both Rapamycin and LY294002 induced CD62-L upregulation in TofDC, there 
could very well be differences in terms of functional outcome based on the mechanism of 
action of these inhibitors. While PI3K inhibition conferred on TofDC the ability to cut CD25 
expression in naïve T cells, mTOR inhibition by Rapamycin on these same cells in parallel 
could not confer this functionality. Also of interest was the observation that functionally, in 
terms of inhibition of CD25 expression, TofiDCs were as potent as TofB (Figure 3.6a).  
We next investigated the regulatory capabilities of TofiDC as well as TofDCs treated with 
PI3K or Rapamycin inhibitors in terms of T cell proliferation as can be judged by CFSE 
dilution using an inhibitory assay run for 72h. Our results show that the TofiDCs were 
functionally equivalent to TofBs as both cell models equally inhibited about 70% of naïve 
CFSE stained T cells from proliferating when stimulated with antigen carrying DCs. In 
control conditions, i.e. in the absence of these cells, 96% of naïve T cells assayed did 
proliferate under the influence of DC stimulation. Interestingly, TofDC+LY294002 strongly 
reduced the proliferatory potential of stimulated naïve T cells as only 24% of such cells were 
able to divide in the presence of LY294002 treated TofDC. This was in contrast to 
TofDC+Rapamycin treated cells which could not inhibit proliferation to the same extent and 
potency as TofDC+LY294002. 82% of naïve T cells did proliferate under DC stimulation 
even when co cultured with TofDC+Rapamycin (Figure 3.6b). Statistical analysis of this data 
showed that TofB, TofiDC and TofDC+LY294002 very significantly inhibited naïve T cell 
proliferation while TofDC and TofDC+Rapamycin had no significant effect on the 
proliferation of the same T cells in separate pools (Figure 3.6c).  
                                                                                                                                                                                      
77 
Taken together, our results showed the TofiDC to be a functional equivalent of TofBs and 
also strongly indicated that blockade of the PI3K but not mTOR signaling cascade is 
responsible for the induction of iTregs in our model system.  These results further bring into 
focus the role and underlying functioning of the PI3K signaling pathway in the induction of 
iTregs so far studied in this body of work. 
 
 
a) 
 
 
b) 
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c)  
          
Fig 3.6 Functional characterisation of TofiDC and delineation of the involvement of the PI3K and mTOR 
pathways in the acquisition of regulatory function. Co-cultures of CFSE stained antigen specific naïve T cell 
stimulated by DC. Differentially activated T cells recovered by MACS separation were added to test their 
inhibitory/functional capacity on naïve T cells activated by DC over a 72h time course. (A) One representative 
FACS blot depicting the effect of differentially activated and or pharmacologically treated cells on CD25 
expression. (B) One representative FACS blot depicting the effect of differentially activated and or 
pharmacologically treated cells on T cell proliferation. (C) Statistical analysis of the inhibitory effect of 
differentially activated T cells on naïve T cell proliferation show that TofB, TofiDC and TofDC+LY294002 but 
not TofDC and TofDC+Rapamycin exhibit regulatory function. Data for Figure 3.6a-b are representative of 4 
independent experiments and Figure 3.6c represent means + SEM of 4 independent experiments.  
 
3.6 Sub-optimal co-stimulation drives acquisition of regulatory function but exerts 
negligible influence on CD62-L dynamics 
The study so far had identified iDCs which lacked high expression levels of co-stimulatory 
molecules (Figure 3.4) as sharing both phenotypic and functional similarities with B cells 
which also lack co-stimulatory capacity (Reichardt et al. 2007). While activation via co-
stimulatory input does not on its own trigger PI3K signaling which our data indicate might 
play a prominent role in the induction of iTregs in our study model system, it is however 
known that co-stimulation plays a prominent role in fine tuning the activity of the PI3K 
signaling cascade (Garcon et al. 2008;Riha and Rudd 2010). It was therefore interesting to 
further investigate the role of the lack or absence of co-stimulatory input into the induction of 
iTregs vis a vis upregulation of CD62-L in our system.  
 
                                                                                                                                                                                      
79 
a) 
            
b) 
                 
c) 
                  
Fig 3.7 Role of co-stimulatory input in acquisition of regulatory behaviour and migratory potential of 
iTregs. Co-cultures of all 3 model cell types were created in the presence and absence of soluble CD28. 
Recovered differentially activated T cells were used in inhibition assays or analysed for CD62-L expression. (A) 
One representative FACS blot showing the effect of augmented CD28 stimulation on the acquisition of 
regulatory behaviour. (B) Statistical analysis of the impact of augmented co-stimulation on acquisition of 
regulatory function. Addition of soluble CD28 led to the significant reduction of regulatory properties of TofB 
and TofiDC but not TofDC. (C) Statistical analysis of the impact of augmented co-stimulation on CD62-L 
dynamics. Addition of soluble CD28 led to transiently significantly increased shedding of CD62-L only the 
TofB at 6h and had no effect on CD62-L dynamics in all cell models long term. Data for Figure 3.7a are 
representative of 4 independent experiments and Figure 3.7b-c represent means + SEM of 4 independent 
experiments. 
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To this end, we added soluble CD28 to cell cultures during the creation of all 3 cell models in 
addition to controls without CD28 i.e. regular TofB, TofDC and TofiDC. After this step, we 
tested the regulatory potency of recovered differentially activated T cells in an inhibition 
assay with naïve T cells triggered by DC. Our data showed that addition of CD28 to TofB and 
TofiDC during the generation phase of these cells led to reduction of the regulatory properties 
of both cell types. Naïve T cells stimulated with DC assayed with TofB and TofDC had 60% 
and 70% of non-proliferating cells as against CD28 augmented TofB and TofiDC which 
could only inhibit 25 and 31% of stimulated naïve T cells from proliferating (Figure 3.7a). 
Statistical analysis of this data showed that in samples co-incubated with TofB+CD28 and 
TofiDC+CD28 there was a significantly increased percentage of proliferating cells when 
compared to the non-CD28 treated TofB and TofiDC. Interestingly, there was no significant 
difference in the rate of naïve T cell proliferation in the presence of TofDC+CD28 and regular 
TofDC samples (Figure 3.7b) thus suggesting that DCs generated in this study had attained a 
“maximum proliferatory and co-stimulatory capacity” that could not be exceeded by the 
addition of soluble CD28 even at the high concentration of 10µg/mL as used in this present 
study. 
Having clarified the role of co-stimulation in the context of regulatory function acquisition, 
we next focused on its role in the migration potential/capacity of the iTregs in our study i.e. 
TofB and TofiDC. We investigated this by again augmenting the co-stimulatory input during 
the generation phase using soluble CD28. At 6 hours after commencement of co-culture, we 
observed that CD28 augmentation induced a significant increase in CD62-L shedding in the 
TofB+CD28 sample in contrast to untreated TofB. At 24h, CD28 augmentation had no effect 
on CD62-L expression (data not shown) as well as at 72h. In both TofDC and TofiDC, there 
was no significant difference observed between CD28 augmented or non-augmented cells 
across all timepoints investigated (Figure 3.7c). 
These results reveal a divergence in the function of co-stimulatory input with respect to iTreg 
generation from naïve T cells. While lack of CD28 activity seemed important for acquisition 
of regulatory function, our data also indicated that it played no discernible role in regulating 
the migratory/homing potential of these cell types as it exerts no influence on the dynamics of 
CD62-L regulation.  
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3.7 Phospho-site specific defective Akt signaling observed following T-cell triggering by 
weak APCs 
Having clarified the role of low co-stimulatory input for the generation of TofB and TofiDC, 
we next turned our attention to better understanding the underlying signaling mechanisms 
driving this induction. Previous data (Figure 3.1) had suggested suboptimal PI3K/mTOR 
triggering following T cell activation as a possible mechanism via which weak APC (naïve B 
cells) drive iTreg production. Examination of the S6 phosphorylation status as surrogate 
readout for the signaling cascade did not yield clear cut results as there was no significant 
difference between iTreg and control and TofB (Figure 3.3). To address in more detail the 
underlying signaling profile in all 3 cell models in focus, we decided to investigate a more 
upstream molecule in this cascade. We focused on Akt phosphorylation dynamics as 
previously studied by Levings and co-workers (Crellin et al. 2007). TofB and TofiDC just as 
TofDC were viable metabolically-active proliferating cells as observed by their expression of 
CD25 (Figure 3.5a). This suggested that they require a system for utilizing nutrients and 
driving metabolism. Such metabolic function is recognized as being dependent on functional 
PI3K/mTOR signaling which is mediated via the agency of the downstream effector Akt 
(Finlay & Cantrell 2010). In view of these observations and reports, it was important to 
understand how suspected sub-optimal PI3K/mTOR signaling could be compatible with 
viability and proliferation as observed in the iTregs of our study.  
Akt kinetics was studied by testing phosphorylation levels of the Akt activation loop at 
Thr308 and the hydrophobic motif at Ser473 following differential activation of naïve T cells 
using all 3 APCs of our study in separate wells. pAkt Ser473 has previously been reported as 
possessing a defective signaling profile in Tregs (Ouyang et al. 2012). In one representative 
experiment, we observed that across all timepoints, levels of total Akt were virtually the same 
with identical expression levels in all 3 cell models.  The phosphorylation status was also the 
same in the pAkt Thr308 activation loop. However, interestingly, examination of the 
hydrophobic motif pAkt Ser473 showed an interesting phenotype. At 6h, TofB, TofiDC and 
TofDC had about 90% pAkt Ser473 expressing T cells. This number dropped down to 30% 
and 26% in TofB and TofiDC at 24h while 70% of TofDC still maintained pAkt Ser473 
expression. On a per cell (MFI) basis, TofB had an expression level of 64, TofiDC 43 while 
TofDC had the highest value of 79. This trend of pronounced pAkt Ser473 deficiency was 
reversed at 72h when pAkt Ser473 levels increased to the high levels of 80-82% in TofB and 
TofiDC while TofDC had about 94% pAkt Ser473 positive T cells (Figure 3.8a-c). 
Statistically, we found significantly reduced pAkt Ser473 levels in TofB and TofiDCs relative 
to TofDC at 24h. At other timepoints examined, when normalized against total Akt 
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expression, there was no significant difference between the profile of pAkt Ser473 of iTregs 
and TofDC (Figure 3.8d-f). 
Put together, these results provided clear indications that there was some form of regulation 
on the PI3K/Akt signaling axis that could be important for Treg induction. 
 
 
 
a)     
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3.8 Temporal upregulation of PHLPP1 drives induction of regulatory function 
Regulation on the level of PI3K/mTOR signaling albeit via transiently defective signaling 
could provide the opportunity for upegulation or downregulation of genes that could be 
important for driving the production of Tregs from naïve T cells. This would also answer the 
question as to how defective PI3K/mTOR signaling could be compatible with sustained cell 
viability and proliferation. The pressing question therefore was by what mechanism(s) are the 
iTregs in this study able to regulate PI3K signaling specifically at one phosphosite? To 
answer this question, we probed the expression of PH domain and Leucine rich repeat Protein 
Phosphatases (PHLPP). PHLPP is a phosphatase which has been recently reported as 
mediating a specific defect in phosphorylation of Akt Ser473 (Patterson et al. 2011). We 
assayed mRNA expression levels as done in the aforementioned study and interestingly 
observed a temporal regulation in the dynamics of PHLPP1 expression in both TofB and 
TofiDC. PHLPP1 mRNA was significantly increased in both iTregs at 6h compared to TofDC 
and was maintained at high levels albeit not significantly over 24 and 72h (Figure 3.9). This 
d) 
 
e) 
 
f)  
 
  
Fig 3.8 Analysis of Akt signaling activity as readout of PI3K/mTOR signaling. TofB, TofiDC and TofDC 
were prepared and acquired as events by flow cytometry following which the T cell population was gated upon.  
(A) Representative FACS blot showing Akt dynamics in T cells after triggering by APC at 6h. (B)  
Representative FACS blots showing Akt dynamics in T cells after triggering by APC at 24h. MFI values of 
pAKT Ser473 are indicated in dotted lines. (C) Representative FACS blots showing Akt dynamics in T cells 
after triggering by APC at 72h. (D) Statistical analysis of Total Akt expression in T cells over indicated the 
timepoints. (E) Statistical analysis of pAkt Thr308 expression in T cells over the indicated timepoints. (F) 
Statistical analysis of pAkt Ser473 expression in T cells over the indicated timepoints.   Data for Figure 3.8a-c 
are representative of 4 independent experiments and Figure 3.8d-f represent means + SEM of 4 independent 
experiments. 
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pattern of expression fitted in with defective pAKT Ser473 at 24h in addition to coinciding 
with the timing of commencement of CD62-L re-expression in both iTregs.  
 
Having observed selective upregulation of PHLPP1 in TofB and TofiDC, we wondered if this 
phosphatase might also be selectively upregulated in TofDC+LY294002 samples which we 
previously showed to exhibit regulatory function of same potency as both TofB and TofiDC 
(Figure 3.6b-c). To this end, we assayed TofDC+LY294002 against regular TofDC for 
expression levels of PHLPP1 mRNA. TofDC+Rapamycin treated samples were also assayed 
given that they induced nominal but non-significant inhibition of naïve T cell proliferation at 
a basal level higher than that obtainable with TofDC as moderating agent in inhibition assays 
(Figure 3.6b).  Interestingly, we observed that LY294002 treated TofDC upregulated 
PHLPP1significantly when compared to levels in TofDC while Rapamycin treated TofDC 
expressed slightly higher but not significant levels of PHLPP1 also (Figure 3.10).    
These results together with fig 3.8 show that induction of regulatory activity is linked to 
PHLPP1 induction. iTreg generation utilizes this transient phase of PI3K/mTOR signaling to 
perhaps tune genes to enhance Treg properties. 
 
                                
Fig 3.9 PHLPP1upregulation underlies defective PI3K/mTOR signaling. At 6h, PHLPP1 mRNA is 
selectively upregulated in iTregs but not TofDC and retains high but non-significant levels at 24 and 72h.  Data 
represent means + SEM of 3 independent experiments.                           
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3.9 Clarifying Foxo1 activity during Treg induction 
3.9.1 Foxo1 is temporarily excluded at early timepoints from the T cell nucleus following 
activation but returns at later timepoints 
Having examined generation of Tregs from naïve T cell pools with focus on regulation of 
CD62-L re-expression dynamics as well as mechanisms governing regulatory behaviour 
acquisition, we decided to examine nuclear related events that could be relevant for CD62-L 
regulation. To investigate this, we turned to the transcription factor Foxo1which apart from its 
known function in CD62-L regulation (Fabre et al. 2005) has recently been demonstrated to 
be relevant for Treg development (Ouyang et al. 2012). Following TCR triggering, Foxo1 is 
exported to the cytoplasm where it is phosphorylated and rendered transcriptionally inactive 
by 14-3-3 proteins (Tzivion et al. 2011). We therefore hypothesized that Foxo1 was excluded 
from T cell nucleus following TCR triggering by all APCs in our study and was re-expressed 
in the nucleus in T cells triggered by weak APC thus leading to CD62-L re-expression while 
being permanently excluded from the nucleus of TofDC which express consistently low levels 
of CD62-L after the initial shedding phase (Figure 3.1). To test our hypothesis, we performed 
nuclear extraction of Foxo1 protein from TofB and TofDC and assayed by western blot after 
establishment of a functional protocol for clean nuclear extraction (Figure 3.11a). Data 
obtained indicated that while as expected the nucleus was depleted of Foxo1 following TCR 
signaling just as shown by Fabre at al. 2005, there was an unexpected finding as we observed 
that Foxo1 was again present in the nucleus of both TofB and TofDC at 24 and 72h at levels 
(Figure 3.11b). 
                                     
Fig 3.10 PHLPP1 is upregulated by PI3K but not Rapamycin inhibition. Addition of LY294002 but not 
Rapamycin leads to the significant induction of PHLPP1 in TofDC. Data represent means + SEM of 3 
independent experiments.                                             
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a) 
  
 
   
 
b) 
 
            
Fig 3.11 Foxo1 is re-expressed in the nucleus of activated T cells. (A) Control test confirming good technique 
for extraction of nuclear protein from T cells. (B) Foxo1 expression levels in TofB and TofDC showing 
exclusion at 6h and return at later timepoints. Data are representative of 3 independent experiments.   
 
To confirm this rather unexpected finding of Foxo1 being present in the nucleus of TofDCs 
which we hypothesized had permanently excluded Foxo1thus its consistently low expression 
of CD62-L, we performed microscopic studies on differentially activated T cells at 6 and 24h.  
In all 3 cell models at 6 hours of co-culture, there was enriched expression of Foxo1 at the 
exterior of the nucleus as depicted by DAPI staining with less Foxo1 visible in the region co-
localized with DAPI staining. At 24h, there was a marked loss of this concentric ring of 
enriched Foxo1 around the DAPI staining which was observable at 6 hours with more Foxo1 
now been visible in the region of the cell co-localized with DAPI (Figure 3.12a). 
Quantification of Foxo1 levels in the nucleus indeed showed that there was more Foxo1 
present in the nucleus of all 3 differentially activated T cells at 24h compared to 6h (Figure 
3.12b).  
These results fit in with the concept of initial nuclear exclusion of Foxo1after TCR triggering 
and then subsequent re-appearance at later timepoints even in the presence of sustained PI3K 
signaling.    
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b) 
       
Figure 3.12 Confirmation of presence of Foxo1 in the nucleus of activated T cells. (A) Apotome 
immunofluorescence microscpy images of differentially activated T cells at indicated timepoints showing 
enrichment of Foxo1 outside the nucleus at 6h after TCR triggering and loss of Foxo1 cytoplasmic enrichment as 
well as increased expression of nuclear Foxo1 at 24h. (B) Quantification of Foxo1 expression level in 
differentially activated T cells. Naïve T cell nuclear Foxo1 expression level was assigned a nominal value of 1 
and data is represented as arbitrary unit (AU) relative to expression level in naïve T cells. Data in Figure 3.12b is 
Means + SEM of 12-14 T cells quantified for nuclear Foxo1 expression.  
 
3.9.2 TCR triggering leads to global changes in DNMT expression 
With the observation of Foxo1 been present in the nucleus of activated T cells, we sought to 
better understand this phenomenon. It has been described that the forkhead box O 
transcription factor family of which Foxo1is a member can be regulated epigenetically 
(Daitoku et al. 2011).  We hypothesized that indeed Foxo1 could be re-expressed in the 
nucleus but epigenetically modulated such that while it was able to bind onto the promoter 
locus of KLF-2 in iTregs and thus drive CD62-L transcription, it was unable to bind onto the 
KLF-s locus in TofDC. To explore this possibility, we began with studying the dynamics of 
DNA methylation as this is the most common and widely studied epigenetic modification 
(Singal and Ginder 1999).   In order to gain insight into DNA methylation dynamics, we 
assayed global mRNA levels of DNMTs in differentially activated cells against expression 
levels in naïve T cells.  
Measurement of DNMTs mRNA showed that 6h after T cell activation, both de novo DNMT 
levels were 3 to 8 times higher in all 3 cell models than in naïve T cells which were assigned a 
value of 1.  At 24h, there were 4-5 times more de novo DNMTs expressed in TofB, TofDC 
and TofiDC  but at 72h, de novo DNMT mRNA expression dropped down to same levels as 
in naïve T cells (Figure 3.13a-b). The converse was the case with the maintenance transferase 
DNMT1 which at 6h remained at same level as in naïve T cells but rose to levels 2 to 5 times 
more at 24h and remained high at 72h with values ranging from 2-4 times above naïve T cell 
DNMT1 mRNA level (Figure 3.13c). 
                                                                                                                                                                                      
90 
These results while unable to give pinpoint details about the DNA methylation status at a 
specific gene locus did provide hints that following TCR priming there was a re-arrangement 
of the DNA methylation pattern to perhaps fit in with future cell fate requirements as 
observed with the initial surge and fall in expression levels of de novo transferases (DNMT 3a 
and DNMT 3b) which form hemi-methylated residues and then  increased expression of the 
maintenance transferases (DNMT 1) at later timepoints which then make the methylation 
pattern permanent and by extension maintain differentiated cell lineages.  
 
 
a) 
                        
b) 
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c) 
                          
Fig 3.13 Global mRNA expression levels of DNMTs following differential T cell activation. (A) DNMT3a 
mRNA expression level in differentially activated T cells. (B) DNMT3b mRNA expression level in differentially 
activated T cells. (C) DNMT1 mRNA expression level in differentially activated T cells. Data represent means + 
SEM of 3 independent experiments.                                              
3.9.3 Global DNA hypomethylation selectively upregulates CD62-L  
Having established that Foxo1 is retained in the nucleus of activated T cells even in the 
presence of sustained PI3K signaling as evidenced by high expression of phosphorylated Akt 
along with the fact that there is some form of regulation on the level of DNMTs during the 
activation process, we decided to home in on the role of epigenetic mechanisms in CD62-L 
regulation. To accomplish this we induced hypomethylation of the genome using the 
pharmacological agent Decitabine. Decitabine (5-aza-2'-deoxycytidine, generic name: 
Dacogen) is a DNMT inhibitor commonly used to study re-expression of genes silenced by 
promoter methylation (Yang et al. 2001) and functions by sequestering DNMT1 to 5-aza-dC 
substituted DNA by irreversible binding of cysteine in the catalytic domain of the DNMT1 
enzyme to the 6 position of the cytidine ring thus preventing the methylation of cytosine by 
DNMTs (Juttermann et al. 1994). Thus if indeed DNA methylation regulates CD62-L 
dynamics, then especially in the case of TofDC there should be upregulation of CD62-L 
following hypomethylation of the genome by Decitabine.  
Following addition of Decitabine to cell cultures during the generation phase of our study cell 
models, CD62-L levels remained unchanged in TofB and TofiDC after 72h with 82% and 
70% CD62-L expressing T cells respectively. In contrast, genomic hypomethylation led to 
increased CD62-L expression in the TofDC population with values rising from 16% in 
untreated conditions to 30% in Decitabine treated TofDC, representing a raise of about 95%. 
We also measured CD25 levels across all 3 cell models and it was largely unaltered in both 
treated and untreated conditions with values ranging between 83-95% CD25 expressing T 
cells thus indicating that Decitabine treated T cells were still viable. 
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3.9.4 CD62-L is independent of HDAC inhibitor activity 
Another common epigenetic modification we investigated for its involvement in CD62-L 
regulation was histone acetylation. Since we suspected gene repression as the possible 
mechanism via which histone acetylation might inhibit CD62-L expression in the in presence 
of total Foxo1 in the nucleus, we focused on HDACs which are generally associated with 
gene silencing (Moreira et al. 2003). HDACs function by removing acetyl groups from 
histone tails thereby making the chromatin more positively charged thus increasing the 
strength of association between DNA and the chromatin. Ultimately, this leads to very tight 
bonding that blocks access of transcription factors to promoter sites (Richon and O'Brien 
2002). In view of the above facts, we utilized the HDAC inhibitor (HDACi) Trichostatin 
(TSA) to induce chromatin opening in order to understand the role of suspected acetylation-
linked gene repression in CD62-L regulation.  
We read out CD62-L expression at 72hours after incubation in the presence of TSA for the 
last 16 hours of incubation of T cells with different APC. Our data could exclude a role for 
HDAC activity in CD62-L regulation as addition of the inhibitor TSA had no influence on 
CD62-L expression levels in all 3 cell models; CD62-L levels remained at the same levels, 
both in plus or minus TSA samples. This was in contrast to the upregulation of CD62-L in 
         
 
Fig 3.14 Genomic hypomethylation leads to upregulation of CD62-L levels in TofDC but not iTregs. 
All 3 cell models were treated with Decitabine and CD62-L expression measured at 72h. DNA 
hypomethylation led to doubling of CD62-L expression in TofDC but had no effect in iTregs. CD25 
expression was unaffected. Data are representative of 3 independent experiments.   
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TofDC treated with Decitabine which was observable once again in this experimental run, 
confirming data from Figure 3.14. We then tested for synergism between HDACs and 
DNMTs as HDACs have been demonstrated to interact synergistically with DNMTs to 
promote gene silencing (Robertson et al. 2000;Rountree et al. 2000).   Synergistic application 
of Decitabine and TSA yielded values which were not different from those obtained with 
Decitabine addition alone thus excluding a possible synergistic effect of both inhibitors in the 
regulation of CD62-L (Figure 3.15).  
                     
Fig 3.15 HDAC activity is dispensable for CD62-L regulation.  T cells triggered by different APCs for 
72h were treated with TSA at the 56h timepoint and CD62-L levels were measured by FACS. Addition of 
TSA had no effect on CD62-L expression level and when applied in synergy with Decitabine showed no 
synergistic effect. Data are representative of 2 independent experiments.  
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3.9.5 Methylation specific PCR of KLF-2 CpG islands in naïve and differentially 
activated T cells 
With data from experiments with Decitabine indicating a possibility that DNA methylation 
could play a role in CD62-L transcription, we decided to examine the KLF-2 locus of the T 
cell genome to identify CpG islands that might be important in the context of this study. By 
gene mapping (supplementary figure 1-2), 2 CpG islands on the mice KLF-2 locus were 
identified, methylation primers designed and samples probed and analysed  together with Dr 
Juliane Weski of the Institute for Experimental Immunology and Imaging, Uniklinikum 
Essen.   Naïve T cells which, based on our hypothesis, should possess a methylation free 
KLF-2 locus served as control while the KLF-2 locus of TofDC with consistently low 
expression levels of CD62-L ought to be methylated thus inhibiting CD62-L transcription. 
We also hypothesized that both iTregs in our study would possess a hypomethylated KLF-2 
locus as in naïve T cells which would be permissive for CD62-L transcription. Given that 
DNA methylation is a heritable and thus transferable trait, we focused on just the 72h 
timepoint as all cells at this point in the culture would have terminally differentiated and 
should therefore be equipped with all the necessary epigenetic signatures driving underlying 
their differentiation. Tested experimentally, our data albeit preliminary showed that in CpG 
island 1 of naïve T cells there was very low level methylation which would hypothetically 
allow for gene transcription but  TofB, TofiDC and TofDC shared more or less the same 
amount of methylation status (Figure 3.16a). Examination of CpG island 2 showed a minimal 
amount of methylation in naïve T cells while both iTregs showed the same amount of 
methylation. Interestingly and contrary to projections, the KLF-2 locus in TofDC was totally 
unmethylated (Figure 3.16b). 
Overall, our results suggest that the KLF-2 locus shares the same status in both effector T 
cells and iTregs of this study, and may thus not be the optimal target for understanding the 
mechanism via which Decitabine was able to able to upregulate CD62-L in TofDC as 
demonstrated in Figures 3.14 and 3.15. 
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a) Methylation pattern of KLF-2 CpG Island 1 
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 TofB 
 
 TofiDC 
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b) Methylation pattern of KLF-2 CpG Island 2 
 Tnaive 
 
 TofB 
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3.9.6 Role of miRNA let-7b in CD62-L regulation 
Epigenetic regulation of CD62-L has also been linked with miRNA expression. Under 
conditions of Mycobacterium ulcerans infection, mycolactone, a macrolide produced by this 
pathogen leads to T cell depletion as well as loss of CD62-L and downregulation of let-7b 
RNA levels. This downregulation of CD62-L was reversible when cells were treated with 
miRNA let-7b (Guenin-Mace et al. 2011). We therefore postulated that following T cell 
activation, let-7b is downregulated in iTregs as well as TofDC but while it remains 
consistently downregulated in TofDC, it is re-expressed in iTregs. To test our hypothesis, we 
quantified miRNA let-7b RNA levels in TofB and TofDC and found that it was equally 
expressed in both cell models and followed the same trend after T cell activation. While at 6h 
after commencement of co-cultures, let-7b expression remained at naïve T cell levels, at 24 
and 72h let-7b levels were downregulated in both cell models at values of about 60% and 
70% respectively (Figure 3.17). 
These results indicated that under conditions of T cell activation, irrespective of the inducing 
APC, let-7b activity is dispensable for CD62-L regulation.  
 TofiDC 
 
 TofDC 
 
Fig 3.16 Methylation patterns of KLF-2 CpG Islands in naïve and 72h differentially activated T 
cells. (A) Methylation pattern from CpG island 1 (B) Methylation pattern from CpG island 2. Black dots 
represent methylated clones while white dots represent unmethylated clones. Data depicts 1 independent 
experiment. 
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Fig 3.17 CD62-L regulation is independent of let-7b. Naive T cells activated by either B cells or DCs equally 
downregulate let-7b thus excluding a role of this miRNA in CD62-L regulation. Data represent means + SEM of 
3 independent experiments.      
 
3.10. Modulation of T cell activation dynamics by the microenvironment 
Work reported so far in this thesis had addressed T cell signaling mechanisms upon activation 
by APCs of different strengths and functional outcomes thereof in an in vitro setting. In vivo, 
T cell activation occurs in SLOs which are composed of stromal cells and adhesive molecules 
and integrins such as ICAM 1 and LFA-1 (Reichardt et al. 2010; Reichardt et al. 2013). In this 
part of the thesis we set out to begin understanding in more detail the dynamics of T cell 
activation under conditions where these adhesion molecules and or stromal cells are defective 
or missing. To begin with, we tested T cell activation dynamics in the context of ICAM 1 
knockout using ICAM
-/-
 knockout mice. Here we adoptively transferred a predetermined 
number of wildtype DCs with or without pOVA and at later timepoints wildtype naïve T cells 
into wildtype and ICAM knockout mice so the only difference in the experimental set up was 
the lack of ICAM on the stroma of the ICAM deficient mice. Thus the aim of this round of 
experiments was to observe if ICAM on the stroma of the SLO plays any role in T cell 
activation in vivo.  
Following on from experimental protocol, popliteal lymph nodes (PLN) from all experimental 
animals were recovered and CFSE stained T cells were analysed from both ipsi and contra 
lateral nodes. In the no pOVA control sample, there was basal homeostatic proliferation of 
4.2% T cells and 1.4% T cells in ipsi and contralateral nodes. When specific antigen was 
introduced, 23% of T cells in the ipsilateral lymph node of the ICAM ko mice proliferated 
while in wildtype C57Bl/6 mice 35.6% of T cells proliferated representing a difference of 
about 30% in proliferation between both mice types. Interestingly, in the contralateral node, 
there was an observed discrepancy as more proliferating T cells (10.5%) were found in the 
contralateral nodes of wildtype mice compared to 3.2% of proliferating T cells in the 
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contralateral nodes (Figure 3.18a). In a wild type host, T cells proliferated one cycle more in 2 
out of 3 experiments compared to ICAM deficient host further depicting the difference in 
efficiency of activation in wild type compared to ICAM deficient host. When subjected to 
statistical analysis, the number of proliferating T cells were found to be significantly more in 
wildtype mice compared to ICAM ko mice (Figure 3.18b).  Examination of these CFSE 
stained T cells on the basis of per cell expression of CD25 showed no significant difference 
between activation status of T cell adaptively transferred and activated in wildtype or ICAM 
ko mice (Figure 3.18c).  
These results gave strong hints that ICAM deficiency in the microenvironment of SLOs could 
play a role in tuning the immune response as evidenced by disparity in the difference in rate 
of T cell proliferation in the presence or absence of ICAM. This role might however be 
restricted to only the rate of proliferation and not the ability to bring cells to full activation 
status as evidenced by expression of CD25.  
 
 
a)   
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b) 
                      
C) 
                   
Fig 3.18 Modulation of T cell activation in ICAM deficient in vivo microenvironment. Adaptively 
transferred CFSE stained T cells were recovered and analysed by FACS after activation for 72h in vivo. (A) One 
representative FACS blot of T cell proliferation activated in the presence or absence of ICAM. (B) Statistical 
analysis of T cell proliferation rates in the presence or absence of ICAM. (C) Statistical analysis of MFI values 
of CD25 expression in T cells activated in the presence or absence of ICAM. Data for Figure 3.18a are 
representative of 3 independent experiments and Figure 3.18b-c represent means + SEM of 3 independent 
experiments. 
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4.  DISCUSSION 
 
This thesis was designed to elucidate the mechanisms governing the differentiation of naïve T 
cells triggered by weak APCs into Tregs as against an effector phenotype when activated by 
LPS matured DCs. Aside the ability of Tregs from the previously published work of our 
group to suppress naive T cell proliferation, significantly inhibit heart transplant rejection as 
well as ear swelling, both Tregs and Teff  cells expressed similar levels of CD25 and CD69 
and the only difference observed between both cell types was the significantly higher level of 
CD62-L in TofB compared to TofDC after 72h of activation (Reichardt et al. 2007). The ease 
of the system for generation of TofB and TofDC with 72h of co-culture thus leant itself as a 
model for the kinetic study of the dynamics of Treg generation from naïve T cells.  Tregs are 
a very unique subset of T cells as they modulate the amplitude of the response from other T 
cells thus occupying a special niche in adaptive immunobiology.  The concept, activity and 
mechanism of action of Tregs has been extensively studied and described (Bilate and Lafaille 
2012;Josefowicz et al. 2012). However, despite all that is presently known about Tregs, not 
much is known about the underlying early cellular signaling events that occur in the process 
of transformation from naïve T cell to iTregs.   
 
Aside the regulatory subset of T cells, there are also reports of regulatory subsets in other 
immune cell types such as regulatory DCs which have been shown to induce Tregs, inhibit T 
cell proliferation as well as induce anergy in T cells (Qian et al. 2012). Regulatory B cells as a 
subset have also discovered and described (Yang et al. 2013;Yoshizaki et al. 2012). This 
understanding brings into perspective the fact that regulatory subsets are perhaps intrinsically 
linked to the immune system in a checks and balance manner to prevent exaggerated immune 
responses which lie at the root of autoimmune conditions among other conditions which 
distort homeostatic regulation of biological processes. In view of the lack of insight into the 
underlying early signaling events driving iTreg development, this study set out to bridge this 
gap using a kinetic study of developmental dynamics from naïve T cells to iTregs with the 
CD4+CD25+Foxp3- phenotype profile. This work built upon previous work from our group 
where B cells were used as APC to trigger antigen specific T cells to produce the regulatory 
TofB and incorporated the more physiologically relevant iTreg produced by T cell triggering 
with iDC (TofiDC) (Etemire et al. 2013). To test the robustness of our concept and study, we 
replicated our data in 2 genetically different mouse strains on the Balb/C and C57Bl/6 
backgrounds with very similar results in both strains thus excluding the chances of our 
observations being skewed by strain specificities or differing genetic composition.  
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Using our model cells we found that naïve T cells differentiating into Tregs utilized similar 
pathways as that leading to effector T cell induction, the only difference being the temporal 
modulation of signaling intensity of the PI3K/Akt pathway. In both iTregs of this study i.e. 
TofB and TofiDC, there was a transient reduction of activity in the PI3K/Akt signaling 
pathway between 6 and 24h, specifically at Akt Ser473 site while the activation loop at 
Thr308 was unaffected by this defect. This phosphosite-specific defect in Akt Ser473 has 
been reported in Foxp3+ Tregs (Crellin et al. 2007) and has been determined to be due to the 
activity of the novel molecule, PHLPP1 (Patterson et al. 2011).  PHLPP is a phosphatase 
consisting of 2 isoforms; PHLPP1 and PHLPP2 which both control the extent and temporal 
effects of Akt signaling by catalyzing the dephosphorylation of the hydrophobic Ser473 motif 
which is a C-terminal phosphorylation switch that plays a vital role in the control of the Akt 
kinase (Brognard and Newton 2008). While the work of Crellin and co-workers identified 
defective Akt Ser473 in fully established Foxp3+ Tregs, this work has identified this same 
molecular signature during the process of development of naïve T cells into potent Foxp3- 
Tregs.  
 
Akt is downstream of the PI3Kinase and is thus influenced by the activity of PI3K following 
T cell activation. While in effector T cells the role of PI3K activity is much more understood 
(Han et al. 2012), its role in Treg development is still subject to intense discussion as there are 
divergent reports on the function of this pathway in Treg development. While it has been 
published that PI3K activation inhibits Treg development (Littman and Rudensky 2010), there 
is also data indicating the opposite (Soond et al. 2012). Data from our study provide new 
insight into these discrepant reports as our data indicate that PI3K is important for and 
compatible with Treg induction. In our model, weak APCs expressing sub-optimal levels of 
co-stimulatory molecules relative to DCs were able to drive naïve T cells into the Treg 
lineage by inducing low intensity Akt signaling for the first 24h after commencement of co-
culture which later increased to levels same as observed in effector T cells. Co-stimulation as 
an extra signaling input from APC to T cells while not a direct downstream effector of the 
TCR has been reported as being relevant for fully potent and optimal PI3K activation (Garcon 
et al. 2008). Further exploring the role of CD28 i.e. co-stimulatory input in our study, we 
observed that augmentation of CD28 levels in cultures with weak APCs activating T cells 
indeed established a role for co-stimulation in Treg development. Addition of CD28 to 
cultures with weak APC and T cells skewed differentiation away from regulatory cell fate 
towards an effector lineage as seen with TofB and TofiDC incubated with soluble CD28 
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which showed with significant loss of inhibitory capacity when tested functionally in T cell 
proliferation.  These results indicate that low levels of CD28 signaling coupled with TCR 
triggering generate a signal sufficient enough to drive T cell differentiation which favours 
acquisition of regulatory function and is in agreement with other published data (Pletinckx et 
al. 2011). Interestingly, this model of low co-stimulatory input as being important for Treg 
development might be only applicable to iTreg generation as thymus developing Tregs have 
been demonstrated to require CD28 input for proper development and functioning (Guo et al. 
2008;Zhang et al. 2013) and iTregs have been demonstrated to require the absence of CD28 
for their induction (Semple et al. 2011). This divergent role of CD28 is therefore dependent 
on the type of Treg being developed i.e. iTreg vs nTreg. Aside the requirement of co-
stimulation for conferment or inhibition of regulatory functionality, CD28 is also important 
for Treg survival and homeostasis (Guo et al. 2008). Thus we postulate that weak APCs 
deliver enough co-stimulatory input to not only induce Tregs but to ensure their survival as 
both iTregs in this study were viable cells as gauged by their high expression of CD25. The 
fact that PI3K activity in both iTregs as measured by its downstream effector Akt reached 
values similar to that in effector T cells after an initial time of reduced activity, strongly 
suggests that there exists a time dependent window of sensitivity in triggered T cells within 
which cell fate decisions driving generation of Tregs are made. This window of opportunity 
could be a time within which cellular machinery necessary for sub-serving regulatory function 
is mobilized and set in place. 
 
One distinguishing character of the iTregs in this study was the re-expression of CD62-L after 
an initial shedding phase which occurred vis a vis full activation as measured by CD25 
expression and T cell proliferation. There was an initial TACE-mediated shedding phase in 
iTreg development as in TofDC but starting at 24 hours the cellular processes began to differ 
as while the iTregs re-expressed CD62-L, in effectors this molecule was consistently down-
modulated (Etemire et al. 2013). An interesting observation in this study was the fact that 
commencement of CD62-L re-expression began at about the same time period when PHLPP1 
mediated pAkt Ser473 defective signaling was most observable. The concept of PI3K/Akt 
attenuation being relevant for the generation of Tregs has been proposed by researchers in the 
field (Soond et al. 2012; Ouyang et al. 2012). Soond and co-workers propose that this 
attenuation of PI3K/Akt signaling allows for the re-expression of the transcription factor 
Foxo1 which then binds onto the Foxp3 locus to induce Treg induction.  
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In the context of our study, Foxo1 was indeed found to be in the nucleus of Tregs where we 
suspect that it binds onto the KLF-2 locus to drive CD62-L upregulation. Interestingly and 
contrary to expectations, we also observed the presence of Foxo1 in the nucleus of the 
effector TofDC. This finding was unexpected as CD62-L which is Foxo1 driven remained 
downregulated in this cell model. Foxo1 has been reported as being permanently excluded 
from the nucleus by PI3K/Akt activity following TCR activation (Fabre et al. 2005). 
However, this study performed imaging for 7 hours and while our data concur with this 
nuclear exclusion at this timepoint, we observed a re-appearance of Foxo1 at the later 
timepoints of 24 and 72h even in the presence of consistent PI3K/Akt signaling as determined 
by continual expression of phospho-Akt. This finding thus caused us to postulate that perhaps 
Foxo1 is subject to some form of epigenetic regulation with respect to CD62-L dynamics. 
Exploring epigenetic influence on CD62-L in terms of DNA methylation and histone 
modification using the pharmacological agents Decitabine and TSA respectively, our data hint 
that DNA methylation but not histone modification does play a role in CD62-L regulation as 
DNA hypomethylation under the influence of Decitabine doubled the amount of CD62-L 
positive cells in the effector T cell pool in our study but not in the iTregs. A search of 
literature revealed that there has been no reported/published study on the role DNA 
methylation or histone modification in CD62-L regulation to date. Thus in view of this, this 
current work offers some new insight into a mechanism that could play a role albeit 
undetermined in T cell migration and localization.  
 
Despite the dearth of information on the possible role of DNA methylation in CD62-L 
regulation, Syrbe et al. 2004 have demonstrated that genomic hypomethylation  by Decitabine 
genome induced a 20 fold increase in P-selectin expression levels of effector T cells activated 
with APC thereby establishing a role for epigenetic modification in the regulation of homing 
activity of T cells. The fact that CD62-L expression could be upregulated under 
hypomethylating conditions might be of clinical relevance as the drug Decitabine is widely 
used in cancer treatment regimens (Christman 2002;Ganesan et al. 2009) and T cell 
distribution has been described to play a role in cancer prognosis (Gu-Trantien et al. 
2013;Matkowski et al. 2009;Naito et al. 1998). Another epigenetic factor investigated still in 
the context of CD62-L regulation was the miRNA let-7b which has been reported to 
upregulate CD62-L (Guenin-Mace et al. 2011). Not much is known nor has been reported in 
literature about the role of miRNAs in CD62-L dynamics and in this study, we could exclude 
differential expression of let-7b as a factor driving the divergent CD62-L characteristics of 
iTregs and effectors. Ultimately, these data hinted at a role for epigenetic regulation in some 
                                                                                                                                                                                      
104 
aspect of CD62-L regulation but the precise location of this modification is yet unclear as 
investigation of the methylation status of 2 identified CpG islands on the KLF-2 locus onto 
which Foxo1 binds in the nucleus using MSP showed no differential methylation patterns. 
This then opens up the possibility that perhaps the epigenetic modification might be located 
on the Foxo1 protein itself. There is published data showing that Foxo1 does have its DNA 
binding capacity epigenetically altered following PI3K/Akt signaling or (Matsuzaki et al. 
2005;Van Der Heide et al. 2004). Both reports also identified acetylation and phosphorylation 
as common modifications of Foxo1 but there are no reports yet of methylation modification in 
this protein. 
 
Another interesting epigenetic linked phenomenon in our study was the absence of Foxp3 
expression in both the TofB (Reichardt et al. 2007) and TofiDC. Foxp3 expression in Tregs is 
epigenetically regulated (Huehn et al. 2009;Polansky et al. 2008) and is driven by Foxo 
proteins (Harada et al. 2010). Roncarolo and co-workers have shown that immature DCs 
when used as APCs, convert naïve T cells in an allogeneic setting into Foxp3- CD25
low
 Tr1 
like Tregs under the influence of IL-10 (Levings et al. 2005). These examples bring to bear 
the plethora of possibilities and avenues via which Tregs can be induced and it remains to be 
determined what in vivo scenarios may promote or predispose the use of each of these 
systems for the generation of Tregs. There could also be the possibility that based on location 
in vivo as well as secretions from cells types in the locality as well as infection or nature of 
immunogenic impulse, different Treg types might be induced. The lack of Foxp3 expression 
in certain Treg populations also brings into focus the changing concept of “master regulator 
factors” for each T cell subset as data accumulate that T cell differentiation exists and 
function in conditions beyond the present one master regulator concept (Oestreich and 
Weinmann 2012). In a recent review, Sakaguchi and co-workers question the designation of 
Foxp3 as the master transcription factor for Tregs based on the fact that there have been 
discovered to be Foxp3+ T cells which do not possess regulatory function (Kitagawa et al. 
2013).  Examples of data challenging the prevalent master regulator concept include reports 
of Foxp3
+
/T-bet
+
 and Rorc
+
/T-bet
+
 T cells (O'Shea and Paul 2010) as well as such works of 
that of Hegazy and co-workers who demonstrate that terminally differentiated Th2 cells when 
adaptively transferred into mice infected with lymphocytic choriomeningitis virus (LCMV) 
become reprogrammed to Gata3
+
T-bet
+
 and IL-4
+
IFN-γ+ T cells and maintain this new 
Th1/Th2 phenotype for months (Hegazy et al. 2010).  
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With the observation that CD62-L is re-expressed on both iTregs in our study we wondered if 
CD62-L re-expression was more than just a phenotypic signature and was perhaps 
intrinsically associated with conferment of regulatory capacity in T cells triggered by weak 
APC. Recently, it was demonstrated by in vitro technique that activation of naïve CD8 T cells 
by a weak APC, liver sinusoidal epithelial cells led to similar CD62-L dynamics as observed 
in TofB and TofiDC i.e. initial downregulation and then re-expression after 24 hours 
(Bottcher et al. 2013). These CD8 T cells homed preferentially to lymph with same potency 
as naïve CD8 T cells which normally express high CD62-L levels. This report coupled with 
our data hint that weak APC might as a rule induce upregulation of CD62-L in T cells after 
interaction and it was thus necessary to begin probing the possible importance of re-expressed 
CD62-L. Additionally, addressing this question was important as there are numerous 
publications which have extensively linked the CD62-L transcription factor Foxo1 with Treg 
generation and development (Harada et al. 2010;Hedrick et al. 2012;Kerdiles et al. 2010) as 
well as being important for function (Samstein et al. 2012). CD62-L as a transcription product 
of Foxo1 has also been discovered and reported to be associated with several functions asides 
homing and migration.  
 
CD62-L plays a role in memory T cell development and activity as it is associated with 
acquisition and maintenance of memory in these cells (Dang et al. 2009;Roberts et al. 2005). 
Additionally, CD62-L expression is linked with development of the key effector function; 
lytic activity in human tumour infiltrating T cells (Yang et al. 2011). Other CD62-L linked 
functions are assistance of virus clearing in CD8 T cells (Richards et al. 2008) as well as 
being vital for maturation and localization of hepatic NK cells during viral infections (Peng et 
al. 2013). Our data from TofDC generated with or without Ly294002 and Rapamycin helped 
to answer this question. Our results showed delineation between CD62-L upregulation and 
acquisition of regulatory function. Rapamycin treated TofDC, despite upregulated CD62-L 
could not inhibit proliferation of naïve T cells stimulated with DCs while the converse was 
the case with Ly294002 treated TofDC which just as the Rapamycin treated cells upregulated 
CD62-L but also showed strong regulatory behaviour unlike the Rapamycin treated sample. 
Our data thus indicate that acquisition of regulatory function is linked more to PI3K activity 
than mTOR signaling.  
 
Patterson et al. converted CD4+ T cells into Tregs by TCR stimulation in the presence of IL-2 
and TGF-β and report that addition of Rapamycin and Ly294002 to the culture induced 
PHLPP1 expression in parallel to Foxp3 induction. Based on this correlation between Foxp3 
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and PHLPP1 expression, they suggested that PHLPP1 upregulation plays a role in Treg 
development. This was experimentally confirmed by ChIP assays where they identified nine 
pututative binding sites on the PHLPP1 promoter for Smad-3. Smad-3 is indeed known to be 
activated during TGF-β induced Foxp3 expression (Tone et al. 2008). In our study, triggering 
of T cell using DCs as APC in the presence of mTOR or PI3K inhibitors led to a significant 
induction of PHLPP1 in only the PI3K inhibited TofDC while mTOR inhibited TofDC 
updated neither PHLPP1 nor exhibited regulatory function. While our data are in agreement 
with that of Patterson et al with regards to the involvement of attenuated PI3K/Akt signaling 
in Treg induction, we find and report that mTOR signaling attenuation is not required for 
induction of Tregs contrary to the report of Patterson et al. One critical point in analyzing this 
study is the fact that TGF-β was added in culture during the generation of these Tregs and 
given that TGF-β has been widely reported to be integral for iTreg differentiation in addition 
to TCR triggering (Zhou et al. 2009), it becomes difficult to disassociate the induction of 
Tregs from naïve CD4 T cells as being solely derived from the activity of this cytokine.  
 
Others have reported on the requirement of mTOR along with PI3K and Foxp3 for induction 
of Tregs (Sauer et al. 2008). This study was conducted using antibody stimulation in contrast 
to our study which was performed using APCs which would in contrast to the strong signal 
associated with antibody stimulation deliver a more delicate input to T cells. There is an 
accumulating body of evidence that signal intensity via the TCR has far reaching and 
divergent consequences for T cell dynamics. Stimulation of the TCR with crosslinked CD3 
has been demonstrated to induce strong stimuli with short lived but intense Erk activation 
while antibodies immobilized on beads induced more tonic signaling with long lasting and 
less intense Erk signaling which was found to induce T cell proliferation and survival at a 
significantly higher level (Arndt et al. 2013; Poltorak at al. 2013). These studies proposed 
immobilized antibody signaling dynamics as being more akin to APC induced signaling 
dynamics and offer new perspectives into possible reasons for the disparity between published 
data and some of the data from our study while highlighting the dynamic range of 
possibilities/outcomes following common TCR triggering in different conditions. One striking 
observation in this study was the fact that Rapamycin failed to induce regulatory function in 
triggered T cells as was obtainable with Ly294002. This finding was highly unexpected as 
Rapamycin is widely used clinically and in basic scientific research for expansion of Tregs 
from CD4+CD25+ cell populations (Battaglia et al. 2005;Battaglia et al. 2006;Battaglia et al. 
2012). Apart from Patterson et al. who showed Treg induction albeit in the presence of TGF-β 
and Rapamycin, Chen et al. 2010 were able to induce Tregs from naïve CD4 T cells in a 6 day 
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co-culture prep with mitomycin treated B cells in the presence of Rapamycin. Based on 
similarities with our study, it is possible that the induction of regulatory function was to some 
extent dependent on the presence of B cells in the T-B co-culture prep. Our results agree with 
other published reports on the requirement of PI3K inhibition for iTreg generation and pose 
new questions with regards to the role of mTOR in this process. Data from mouse T cells with 
frap gene deletion thus lacking mTOR yields some more insight into the role of mTOR in 
iTreg generation.  The frap1 gene encodes the mTOR protein in T cells. These T cells could 
be activated normally and expressed IL-2 but failed to differentiate into Th1, Th2 and Th17 
cells due to deficiency in STAT activity. These mice could generate Tregs but specific T cells 
affected by frap gene deletion which lacked TORC1 and TORC2 showed a pronounced 
inability to differentiate into Tregs (Delgoffe et al. 2009). This result supports our data and 
strongly indicates that the generation of Treg occurs in the presence of intact mTOR activity 
and not in its absence or under conditions of inhibition while also highlighting the central role 
for mTOR in differentiation of T cells.  
 
Investigation of the underlying dynamics of CD62-L control also involved gaining insight 
into the role of co-stimulation in this regard. While we had observed a lack of co-stimulatory 
input from weak APCs to be important for the induction of regulatory function, we also 
clarified the role of CD28 with respect to migratory potential as can be inferred from the level 
of CD62-L expression on primed T cells.  We observed that augmented co-stimulation in both 
iTregs had no influence on CD62-L expression levels. This result placed side by side against 
the loss of regulatory function in iTregs generated with augmented co-stimulation indicates 
that there is some form or compartmentalization in the signaling mechanisms governing 
conferment of regulatory characteristic and homing potential. This dichotomy mirrors the 
divide in the process(es) between acquisition of regulatory function and upregulation of 
CD62-L in TofDC treated with Rapamycin or Ly294002. Mirenda et al. 2007 have reported 
that co-stimulation by CD28 is important for migration of memory T cells to the periphery 
while the data from Fuse et al. 2008 show that CD28 co-stimulation is important for priming 
and recall responses of memory CD8 T cells. Co-stimulation was also found to be important 
for responses to infections with murine gammaherpesvirus 68 (MHV-68) infection. These 
reports complement each other in driving this concept of compartmentalization on two levels; 
the first being that differences in co-stimulation requirement help to divide differentiation 
processes for different T cell subsets and secondly, differences in co-stimulation requirement 
enables T cells to navigate to their site of activity.  In addition to these 2 points, the concept of 
compartmentalization also brings a new perspective to understanding the development and 
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functioning of extranodal regulatory T cells. Extranodal Tregs are distinct from nominal 
Tregs as they are CD62-L negative but express high amounts of E/P selectin binding ligands 
in addition to multiple adhesion molecules and chemokines linked with inflammation. These 
extranodal Tregs as the name indicates do not localize to the lymph node due to lack of 
CD62-L and were described to exhibit the most potent inhibitory activity against 
inflammatory processes in an antigen-induced arthritis disease model (Huehn et al. 2004). 
Based on the localization and described activity of these extranodal Tregs, it takes to reason 
that these cells developed in a manner wherein it acquired regulatory capacity via processes 
independent of CD62-L regulation. 
 
In the last part of this thesis, we began exploring the impact of factors from the 
microenvironment within which T cell activation occurs. T cell activation and function is 
affected and modified based on microenvironmental factors. The input of the 
microenvironment in T cell activity is mostly addressed in the context of tumour-immunology 
with several publications to that effect (Carlson et al. 2013;Fisher et al. 2006;Santin et al. 
2001;Weigelin et al. 2011).  Our data already indicate that absence of the adhesion molecule 
ICAM 1 on lymph node stroma leads to decreased efficiency in T cell activation due to lack 
of sufficient residence time in the lymph node. Questions as to possible outcome in infectious 
conditions and T cell potency and activity under conditions of such altered 
microenvironments using several mouse models would be of interest and could answer 
questions as to whether or not adhesion molecules do more than just firm the interaction 
between T cells and APC and or surrounding structures doing T cell activation dynamics.   
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5.0 CONCLUSION AND OUTLOOK 
 
This thesis set out to investigate the early signaling processes which drive conversion of naïve 
T cells into regulatory T cells and presents data showing that T cells differentiating into either 
Tregs or effector T cells make use of similar signaling patterns. The major difference in terms 
of signal transduction was the tuning of the PI3K/Akt signaling which was found to be 
differentially regulated between iTregs and effector T cells with the phosphatase PHLPP1 
playing a key role in this tuning. Previous work has identified this phosphatase as being 
important for functioning of established Tregs (Patterson et al. 2011) but our data extend this 
finding by suggesting that PHLPP1 is also important for driving the induction of Tregs from a 
naïve T cell pool. PI3K/Akt signaling has been implicated as playing a role in Th17 
differentiation (Kim et al. 2013;Nagai et al. 2013), Th22 differentiation (Mitra et al. 2012) as 
well as the generation of other CD4 T cell subsets (Han et al. 2012). In the case of iTreg 
differention vis a vis generation of the effector TofDC in this study, the differential outcomes 
were based on signaling thresholds with attenuated PI3K activity for the first 24 hours of Treg 
induction following which PI3K activity rose to levels commensurate with that of TofDC at 
later timepoints. In further works on elucidating the role of PHLPP1 in iTreg development, it 
will be important to knockdown this phospshatase by RNAi technique in naïve T cells and 
then study the dynamics and functionality of T cells triggered the same as in this study. 
 
This study was also able to delineate the roles of the PI3K and mTOR signaling cascades in 
the acquisition of regulatory function with our data strongly hinting that regulatory activity is 
more dependent on PI3K activity and independent of mTOR signaling. Along this line, this 
study also established that CD28 co-stimulation plays no role in the induction and homing 
capacity of Tregs but that its absence is required for acquisition of regulatory function. In 
terms of regulatory function the presence of Foxo1 in the nucleus of both iTregs and effector 
T cells requires more thorough investigation in order to understand the precise process 
underlying this phenomenon. While in Tregs, CD62-L a target gene of Foxo1 is 
transcriptionally active while in TofDC, it is not. This pre-supposes that there is some 
inhibitory factor involved in this process. It would be interesting to by pull-down experiments 
investigate the proteins and factors complexed with Foxo1 in both cell lineages as this might 
shed new insight. Foxo1 is a master transcription factor with over 300 known target genes and 
drives many cell intrinsic processes (Ouyang et al. 2012). Given that Foxo1 is not a CD62-L 
dedicated/restricted transcription factor, it is important to understand in more details how it is 
interacts with each of its numerous target genes in different differentiation states/stages.  In 
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the context of our study, we hypothesize that Foxo1 is excluded following T cell activation 
and while it out of the nucleus, the chromatin is remodeled to selectively bind Foxo1 upon its 
re-appearance at later timepoints. This might account for differential expression of CD62-L 
between iTregs and effector T cells generated and analyzed in this present work.  
 
 
 
 
a) 
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b) 
           
        
Fig 5.1 Model for signaling dynamics following activation of naïve T cells by weak or strong APC. (A)  
Schematic depicting signaling early events in T cells triggered by weak APC. PHLPP1 is upregulated after TCR 
triggering, thus reducing PI3K driven Akt Ser473 phosphorylation levels. Foxo1 after an initial nuclear 
exclusion phase re-appears at about 24h in the nucleus and drives CD62-L transcription and the T cells overall 
differentiate into Tregs. (B) Schematic depicting signaling early events in T cells triggered by strong APC. Akt 
Ser473 activity is sustained at a high level under the influence of PI3K activity following TCR triggering and 
Foxo1 after an initial nuclear exclusion phase re-appears in the nucleus but fails to drive CD62-L transcription 
by mechanisms possibly involving DNA methylation and other yet unelucidated factors. T cells thus triggered 
exhibit effector phenotype and function. 
  
 
Finally, we began investigating how the microenvironment modulates T cell activation in 
vivo. Using an ICAM knock out host, we could show that T cells were activated to the same 
levels as obtainable in wildtype hosts by measuring CD25 levels but our data showed that T 
cells in ICAM deficient hosts proliferated significantly less than in wildtypes. This suggests 
that the extent of the immune response might be slower in cases of ICAM deficiency on 
lymph node stroma. Given the nature of immune insults and the need for a prompt response, 
this will have strong functional relevance. Further works will involve recapitulation of this 
assay   in other transgenic mice with defective integrins as well as performing viral and 
infectious studies in these mice to gain a better insight into how T cells respond to infections 
in altered microenvironmental conditions.    
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6.0 ZUSAMMENFASSUNG 
 
Regulatorische T Zellen (Tregs) bilden eine eigene Untergruppe der T Zellen. Ihre 
Hauptaufgabe ist es, Immunantworten zu regulieren und damit auf einem, für den Organismus 
ungefährlichen Niveau zu halten. Prinzipiell kann man regulatorische T Zellen in zwei weitere 
Untergruppen aufteilen: Zum einen in die natürlich vorkommenden Tregs (nTregs), welche 
sich im Thymus entwickeln und zum anderen in induzierte Tregs (iTregs), welche aus dem 
naiven T Zellpool in der Peripherie heranreifen. Ein Hauptcharakteristikum von 
regulatorischen T Zellen ist die Expression des Transkriptionsfaktors Foxp3. Nichtsdestotrotz 
beschreiben neuere Arbeiten auch wichtige immunmodulatorische Funktionen von Foxp3-
negativen Tregs. Obwohl die Gruppe der iTregs in den letzten Jahren Gegenstand vieler 
wissenschaftlicher Arbeiten waren und obwohl viele Details zu ihrer biologischen Funktion 
publiziert wurden existiert eine deutliche Wissenslücke, was die initialen Signalkaskaden 
angeht, welche die Konversion von naiven T Zellen zu iTregs einleiten. Unter Zuhilfenahme 
eines transgenen T Zellmodells (pOVA stimulierte T Zellaktivierung von OT-I/II T Zellen) 
wurden in der vorliegenden Arbeit die Prozesse charakterisiert, welche an der Ausreifung von 
naiven T Zellen zu CD4+ CD25+ Foxp3- iTregs nach Stimulation des T Zellrezeptors (TCR) 
durch schwache Antigen präsentierende Zellen (APC), wie z.B. B Zellen, beteiligt sind.  
 
Die ersten Resultate dieser Arbeit zeigten, dass iTregs nach Aktivierung durch schwache APC 
(B Zellen) zunächst das Oberflächenmolekül CD62-L verloren. Dieses Molekül wird von den 
Zellen benötigt, um effektiv ihren Weg in den Lymphknoten zu finden. Nach 24 h war eine 
Re-Expression des Moleküls nachzuweisen und nach 72 h entsprach das Expressionslevel 
dem naiver T Zellen. Im Gegensatz dazu verloren T Zellen nach starker Aktivierung durch 
reife Dendritische Zellen (DCs) ebenfalls CD62-L, allerdings blieb dieser Zustand über 
mehrere Tage erhalten.  
Basierend auf pharmakologischen Vorarbeiten wurde impliziert, dass der PI3K/mTOR 
Signalweg eine zentrale Rolle bei der unterschiedlichen CD62-L Regulation zwischen iTregs 
und Effektor-T Zellen einnimmt. Hierzu konnten wir zeigen, dass das hydrophobe Motiv der 
Proteinkinase Akt, Ser473, in iTregs nach Stimulation durch schwache APC konstant 
phosphoryliert vorlag. Dieses Aktivierungsmuster ging mit einer Hochregulierung der erst 
kürzlich beschriebenen Phosphatase PHLPP1 einher. Von dieser ist wiederum bekannt, dass 
sie spezifisch die Phosphatreste am Ser473 der Akt angreift. 
Bezüglich der Wichtigkeit der PI3K/mTOR Signalkaskaden fanden wir, dass nach einer 
pharmakologischen Inhibition der PI3K naive T Zellen zu regulatorischen T Zellen 
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ausdifferenzierten. Das Blocken der mTOR Kaskade hatte keine Messbaren Auswirkungen in 
diesem Kontext. 
Als nächstes wurde die Rolle der CD28 Ko-Stimulation bei der Generierung von 
regulatorischen T Zellen untersucht. Hierbei fanden wir, dass ein Fehlen der ko-
stimulatorischen Moleküle bei der Aktivierung von T Zellen durch schwache APC 
unabdingbar für die Ausbildung ihrer regulatorischen Funktionen war. Eine verstärkte CD28 
Stimulation führte zur Aufhebung jeglicher immunregulatorischer T Zellfunktionen. 
Interessanterweise hatte diese Ko-Stimulation keine Auswirkung auf die CD62-L Expression 
in den Zellen. Dieser Befund erlaubt die Schlussfolgerung, dass eine sub-optimale 
Aktivierung naiver T Zellen durch CD28 Ko-Stimulation notwendig für die Ausbildung des 
immunregulatorischen Potentials von iTregs ist, dass durch dieses die migratorischen 
Fähigkeiten der Zelle aber nicht weiter beeinflusst werden. 
Abschließend charakterisierten wir die Rolle von Adhäsionsmolekülen auf Stromazellen bei 
der T Zellaktivierung. Wir konnten zeigen, dass adoptiv transferierte OT-II T Zellen in WT 
Tieren und in ICAM (Intercellular Adhesion Molecule) k.o. Mäusen gleich gut, durch Peptid 
beladene, ebenfalls transferierte DCs aktiviert wurden (Messung des CD25 Levels). Der 
Prozentsatz an proliferierenden Zellen lag in ICAM k.o. Tieren hingegen signifikant reduziert 
vor. Daraus formulierten wir die These, dass T Zellantworten im Lymphknoten deutlich 
verzögert oder ineffektiv ablaufen, wenn das Stroma des lymphatischen Organs kein ICAM 
als „Zellanker“ aufwies. 
 
Zusammenfassend kann gesagt werden, dass die vorliegende Arbeit Einblicke in früh 
ablaufende Signalwege bei der Generierung von iTregs aus naiven T Zellen gibt. Darüber 
hinaus beschreibt sie ein zeitliches Fenster nach T Zellrezeptorstimulation in welchem die 
Höhe der PI3K/Akt Aktivität bestimmt, ob sich eine T Zelle zu einer Effektorzelle oder zu 
einer Immunzelle mit regulatorischem Potential entwickelt. Darüber hinaus wird in der Arbeit 
die These formuliert, dass Adhäsionsmoleküle auf Stromazellen lymphatischer Organe eine 
wichtige Rolle bei der Einleitung von T Zellantworten haben. 
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Supplementary Figures; Gene mapping of the mice KLF-2 locus 
Figure 1. Mouse KLF-2 locus was analysis with GC contents and other determined 
characteristics. 
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Figure 2. Identification of KLF-2 CpG islands and primer sequence target and lenght for 
MSP 
a) CpG Island 1 
 
 
b) CpG Island 2 
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